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3. Summary of study 
Medication is a vital component in the treatment of patients with severe mental disorders, but 
it can be a challenge for clinicians to motivate patients to stay on medication. Nonadherence 
estimates vary between studies and this variation seems to reflect inconsistency in study 
design and methods. This makes it difficult to compare results and limits the generalizability 
of findings. However, some of the variation could also reflect true differences in adherence 
due to characteristics of the samples or the health care systems. Thus, it is of importance to 
measure adherence in large well described samples from different health care systems. It 
seems reasonable that being able to motivate patients to better adhere to their medication 
would improve adherence and thereby reduce suffering and save money. Therefore, it is 
important to understand better why patients do not follow medical advice. Previous studies 
have attempted to indentify predictors of adherence to medication. There are some 
consistencies between the different studies with regards to the different predictors of 
nonadherence, but some inconsistencies as well, and it is still unclear which clinical predictors 
are most important in schizophrenia and bipolar disorder. The measurement of adherence is a 
long standing methodological problem. There are several available methods. Direct measures 
include observing patients swallowing tablets and the measurement of level of medicine or 
metabolites in the blood. Indirect measures cover self reports and electronic medication 
monitors. 
The main object of this thesis was to determine adherence rates in a Norwegian 
catchment area population of patients with severe mental disorders and to identify predictors for 
nonadherence in this population. To be able to do this, several methodological issues needed to 
be solved. This applied to the method of adherence measure, as well as the measure of some of 
the proposed predictors. The Birchwood Insight Scale (IS) used to measure insight and the 
Beliefs about Medicines Questionnaire (BMQ) used to measure beliefs about medication, 
needed to be validated for the patient sample in the current study. The first part of this thesis 
focuses on methodological issues regarding these questionnaires.  
This report is based upon naturalistic data from the cross-sectional part of the 
Thematically Organized Psychosis (TOP) Study, carried out in joint collaboration between the 
University and University Hospitals of Oslo. Inclusion criteria for the TOP Study are broad, 
consisting of 1) being registered in the psychiatric services of any of the 4 University 
Hospitals in Oslo; 2) aged 18 to 65 years; 3) meeting the DSM-IV criteria for any major 
9 
 
psychotic or bipolar disorder; 4) understanding and speaking a Scandinavian language; 5) 
having no history of severe head trauma or neurological disease; and 6) having an Intelligence 
Coefficient (IQ) score over 70.  From May 2003 through October 2006 a total of 385 patients 
were evaluated. Two hundred and eighty met with criteria for the studies of this thesis.  
Acceptable psychometric properties were found for the IS when applied to patients 
with schizophrenia and bipolar I disorder. However, for patients with bipolar II disorder the 
scale seemed to work poorly. The BMQ had satisfactory psychometric properties for use in 
patients with severe mental disorders.   
Multiple adherence measures were used to establish adherence level in the study sample. 
The result was that outpatients with severe mental disorders showed relatively good adherence 
to prescribed medication. In addition, the use of self-report in adherence studies was addressed, 
with the conclusion that simple self report questionnaires seem to be a valid method for 
measuring adherence.  
Regarding the proposed predictors for nonadherence; in schizophrenia, use of illegal 
substances, alcohol, beliefs about medication and poor insight were related to worse adherence. 
Schizophrenia patients with no adherence did better on tests of executive functioning, verbal 
learning and memory and had higher IQ than patients with better adherence. In bipolar disorder 
the use of illegal substances and alcohol and beliefs about medication were related to worse 
adherence. There was a significant association between poor adherence and some autonomic 
side effects; diarrhea, nausea and orthostatism in schizophrenia patients and with orthostatism 
and urine retention in bipolar disorder patients. Otherwise there was no significant relationship 
between side effects and adherence. Fully adherent schizophrenia patients had significantly 
higher BMI than partially adherent patients. In the bipolar patients there was no statistically 
significant difference of mean BMI between the different adherent groups.    
Taken together, the present thesis suggests that insight can be measured with the IS in 
patients with schizophrenia and bipolar disorder, and that beliefs about medicines can be 
measured using the BMQ in patients with severe mental disorders. Further, outpatients with 
severe mental disorders showed relatively good adherence to prescribed medication. In this 
sample substance and alcohol use and beliefs about medication were important risk factors for 
nonadherence in patients with schizophrenia and bipolar disorder. Poor insight was also a risk 
factor, especially in schizophrenia. The results suggest that cognitive dysfunction is not a risk 
factor for nonadherence in these diagnostic groups.  
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4. Abbreviations 
 
ANOVA  one way analysis of variance  
BMI  Body mass index (weight in kg divided by the square of the height in m) 
BMQ  Beliefs about Medicines Questionnaire 
CVLT-II California Verbal Learning Test 
D-KEFS Delis-Kaplan Executive Function System 
DAI  Drug Attitude Inventory  
DSM-IV Diagnostic and Statistic Manual of Mental Disorders, 4th edition  
FGA  First generation antipsychotic 
IDS  Inventory of Depressive Symptoms 
IQ  Intelligence Coefficient  
IS  Birchwood Insight Scale 
MARS  Medication Adherence Rating Scale 
MEMS Medication Event Monitoring System 
MPR   Medication Possession Ratio 
NART  National Adult Reading Test 
PANSS  Positive and Negative Symptoms Scale  
PTA   Primary Therapeutic Agent 
RCT  Randomized Controlled Trial 
SAI-E   Schedule of Assessment of Insight  
SCID-I Structured Interview for the DSM-IV Axis I Disorders 
SGA  Second generation antipsychotic 
SMI  Severe mental illness 
SPSS  Statistical Package for the Social Sciences  
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SUMD Scale to Assess Unawareness of Mental Disorders 
TOP  Thematically Organized Psychosis Study 
UKU  Udvalg for Kliniske Undersøkelser 
WAIS-III Wechsler Adult Intelligence Scale 
WASI  Wechsler Abbreviated Scale of Intelligence 
WHO  World Health Organization 
WMS-III Wechsler Memory Scale 
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5. Introduction 
 
5.1. Perspectives and definitions 
Schizophrenia and bipolar disorder are two very disabling disorders and both are on the 
World Health Organization´s (WHO) top ten global list for disorders causing disability 
("WHO-The global burden of disease 2004 update," 2008). These disorders are responsible 
for more disability than all forms of cancer or major neurologic conditions such as epilepsy 
and dementia of Alzheimer´s type. The reason is primarily because of the early onset and 
chronicity of these disorders across the life span. According to WHO estimates there are 26.3 
million people worldwide that suffer from schizophrenia and the disorder is number 5 for men 
on the list for leading disabilities (years lost to disability) and number 6 for women. 
Schizophrenia is listed in disability class VII which is the highest class with severe disability. 
Twenty nine point five million people globally suffer from bipolar disorder according to 
WHO´s estimates and the disorder is number 7 for men and 8 for women on the WHO list for 
leading cause of disability. This disorder is listed in disability class V with moderate to severe 
disability. The schizophrenia spectrum and bipolar disorders constitute what is often called 
‘severe mental illness’ (SMI) or ‘psychotic disorder’. The adjective ‘severe’ refers to the 
intensity of symptoms, the loss of daily functioning and the persistence over time that may be 
associated with the conditions. 
 
 
5.1.1. Schizophrenia 
This is a disorder known in all settings and cultures. The prevalence of schizophrenia is more 
geographically varied than previously assumed, but it is estimated that 7 individuals per 1000 
will be affected, but gender, urbanicity, latitude and migration have been shown to influence 
incidence rates (McGrath et al, 2008). 
Schizophrenia, as defined in the DSM-IV-TR diagnostic system (Diagnostic and 
statistical manual of mental disorders : DSM-IV-TR, 2000) is a disorder that lasts at least 6 
months and has a presence of a minimum set of characteristic signs and symptoms (both 
positive and negative) for at least a month (active phase). These signs and symptoms are 
associated with marked social or occupational dysfunction. The modal age of onset is between 
18 and 25 years in men, and for women between 25 and the mid-30s (Diagnostic and 
statistical manual of mental disorders : DSM-IV-TR, 2000).  The symptoms of schizophrenia 
13 
 
are commonly divided into positive and negative, but it is now generally accepted that 
cognitive deficits are also a core aspect of the disorder (Fioravanti et al, 2005; Kelly et al , 
2000). The positive symptoms constitute the active psychotic symptoms, the delusions and 
hallucinations, whereas the negative symptoms comprise the affective flattening, poverty of 
speech, lack of motivations and social withdrawal. The negative symptoms account for a 
substantial degree of morbidity associated with the disorder and the positive and negative 
symptoms seem to follow independent courses over time (Eaton et al, 1995). According to the 
definition (DSM-IV) schizophrenia involves dysfunction in one or more major areas of 
functioning. Hence, in patients the functioning is clearly below that which had been achieved 
before the onset of symptoms.  
People with schizophrenia have a higher risk for comorbidity like substance abuse and 
depression and for suicidality, as well as chronic somatic diseases such as cardiovascular 
disease and diabetes. The mortality rate is estimated to be two – three times that of the general 
population (McGrath et al 2008). Schizophrenia is estimated to be responsible for between 1.5 
and 3 % of the direct health care costs in a survey of several western countries, in addition 
there are considerable costs related to lost productivity and impact on the family (Knapp et al, 
2004). According to the WHO website (http://www.who.int/mental_ health/management 
/schizophrenia/en/), more than 50% of people with schizophrenia are not receiving 
appropriate care and 90% of those are in developing countries. 
Schizophrenia remains a major concern within health care because of its severe 
consequence on the life of the patients and their families, and because of its long duration. 
The WHO predicts that schizophrenia will remain among the top ten causes of disability well 
into the twenty-first century. 
 
 
5.1.2. Bipolar disorder 
Even though the prevalence numbers for bipolar disorder vary across studies, the prevalence 
of bipolar I disorder has been thought to be around 1% (Goodwin & Jamison, 2007). Recent 
data from the World Mental Health Survey Initiative, a project of the WHO, show somewhat 
lower numbers. In a cross-sectional household survey of 61 392 adults in 111 countries across 
America, Europe and Asia, the total lifetime prevalences were 0.6% for bipolar I disorder, 
0.4% for bipolar II disorder and 1.4% for subthreshold bipolar disorder (Merikangas et al, 
2011). In this survey there was some cross-site variation in the prevalence rates, but the 
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severity, impact and patterns of comorbidity were remarkably similar internationally. In the 
same survey approximately half of those with bipolar I disorder reported age of onset before 
the age of 25 years and those with bipolar II disorder reported a slightly later age of onset. A 
recent Norwegian study found that the mean age of onset defined as the start of the first 
affective episode was 23 years (Larsson et al, 2010). 
The DSM-IV-TR definition (Diagnostic and statistical manual of mental disorders : 
DSM-IV-TR, 2000) of bipolar spectrum disorders, is based on the identification of mood 
episodes occurring over time. Diagnosis of bipolar I disorder demands the presence of a 
manic episode in the person’s history. In bipolar II disorder there must have been at least one 
major depressive episode and one episode of hypomania. Cyclothymic disorder is a chronic, 
fluctuating mood disturbance involving numerous periods of hypomanic symptoms and 
numerous periods with depressive symptoms that do not meet criteria for a major depressive 
episode. Both mania and major depression may involve psychotic symptoms with delusions 
or hallucinations. Mania and hypomania are defined by a distinct period of abnormally and 
persistently elevated, expansive or irritable mood accompanied by a set of related signs or 
symptoms. Mania is more severe than hypomania, distinguishable by the presence of 
psychosis, hospitalisation or marked impairment in functioning. Major depression is 
characterised by a distinct period of persistent depressed mood or anhedonia, accompanied by 
a set of related signs or symptoms. Presence of psychosis implies higher severity. 
 Bipolar disorder is associated with higher risk of psychiatric comorbidity like 
substance abuse and anxiety disorders and data suggests that 65% of patients with bipolar 
disorder have a comorbid condition (McElroy et al, 2001). In addition patients with bipolar 
disorder have increased risk for general medical conditions like cardiovascular disease, 
pulmonary conditions and diabetes (Perron et al, 2009). There are few comprehensive cost-of-
illness studies that focus primarily on bipolar disorders (Kleinman et al, 2003), but even so it 
is clear that direct medical costs associated with inpatient and outpatient management are 
significant. These costs were estimated to be $7.6 billion in the United States in 1991 (Wyatt 
& Henter, 1995) and in addition there are considerable costs related to the loss of 
productivity. 
Bipolar disorder is like schizophrenia a major concern within health care and is 
predicted to remain on WHOS´s list of top ten causes of disability in the coming years. 
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5.2. Adherence to medication 
5.2.1.   Historical perspectives  
Through centuries and in different cultures men have turned to those with knowledge of 
medicines and healing with their ailments. Remedies and potions have been mixed and 
prescribed, but alongside the desire to get well is the behaviour of being noncompliant and not 
following advice, by not taking what was prescribed, or not taking it as was recommended 
and even taking too much. Perhaps the first example of nonadherence was when Eve ate the 
apple in the garden of Eden. Hippocrates stated that physicians should keep aware of the fact 
that patients often lie when they state that they have taken certain medicines. 
 
5.2.2.   Definitions  
The subject of medication-taking has generated extensive literature and considerable 
controversy. The complexity of the topic is illustrated by the fact that at least three terms are 
commonly used in relation to medication-taking, with little apparent consensus (Horne et al, 
2005). In 1976 Sackett introduced the term “compliance” into medicine. The meaning of the 
term according to the English dictionary is: The act or process of complying to a desire, 
demand or proposal or, to coercion. In the medical context the term is used to describe the 
extent to which a patient takes the medication as prescribed. In Haynes et al´s Compliance in 
health care, the term is defined as “The extent to which the patients´ behavior in terms of 
taking medication, following diets, executing life style changes, coincides with medical or 
health advice (Haynes et al, 1979). This term has been widely used in the past, for the act of 
following treatment instructions. The use of the term has been criticized (Stimson, 1974) as it 
gives the patient a passive role and makes him submissive in his relationship to the physician. 
Based on this argument the term adherence/nonadherence (Barofsky, 1978) has been adopted 
by many in the past few years. According to the English dictionary this term means: “Quality 
of adhering; fidelity, steady attachment”. In a therapeutic alliance the term is defined as: 
Patient acceptance of recommended health behaviours. By using the term adherence it is 
implied that the patient is more active in his own therapy and there is more focus on building 
a good therapeutic alliance. Some have meant there is still a way to go and introduced a third 
term; Concordance (Royal Pharmaceutical Society of Great, 1997), which has a more 
complex definition: “a new approach to the prescribing and taking of medicines. It is an 
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agreement reached after negotiation between a patient and a health care professional that 
respects the beliefs and wishes of the patient in determining whether, when and how 
medicines are to be taken. Although reciprocal, this is an alliance in which the health care 
professionals recognize the primacy of the patient’s decisions about taking the recommended 
medications.”  This term is predominantly used in the UK and has not been adopted into 
mental health studies when addressing the behaviour of taking medication. The term 
adherence has by some experts in the field been recommended as the term of choice to 
describe patients’ medicine taking behaviour (Horne et al, 2005). The WHO has taken the 
same standpoint in their definition: “Strong emphasis was placed on the need to differentiate 
adherence from compliance. The main difference is that adherence requires the patient’s 
agreement to the recommendations. We believe that patients should be active partners with 
health professionals in their own care and that good communication between patient and 
health professional is a must for an effective clinical practice” (WHO: Adherence to long-
term therapies. Evidence for action 2003). In spite of the debate of terms, the terms 
noncompliance and nonadherence have comprised a generally consistent set of core elements 
and include the failure of patients to follow the direction of the health care providers. This 
includes entering treatment programmes, premature termination of therapy and incomplete 
implementation of instructions, including prescriptions and that the goal of the health care 
provider is to treat or prevent a disorder. The main focus of this thesis is on the failure to 
follow medical treatment. 
 Another important definition is that of the extent of adherence or nonadherence. When 
is a patient partially adherent or nonadherent? How many doses of medication does a person 
need to leave out or not take to be categorized as not fully adherent? The weakness of the 
proposed definition of adherence fails to acknowledge that it is not an “all or nothing” 
phenomenon. The term partial adherence acknowledges the common situation in which a 
patient takes some, but not all, of their prescribed medication (Weiden et al, 2004). Many 
patients display a range of adherence behaviours. They may take an amount that is less than 
recommended, taking the correct dose at the incorrect time, taking irregularly (on and off), 
taking gaps or “drug” holidays and stopping the treatment prematurely. Then there are some 
that may take too much. Nonadherence can be intentional (primary) or unintentional 
(secondary) i.e. some patients forget and others decide not to take. When considering long-
term disorders it is unlikely that many patients are 100% adherent at all times, but at what 
level of adherence does the medication not reach the desired effect? This is what is important 
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for the clinical result of the treatment. Not all types of medication are dependent on the patient 
being fully adherent for clinical response. In studies, an adherence rate of 80-90% is 
considered satisfactory, but it is important to bear in mind that adherence behaviour is in its 
nature not a constant but a dynamic phenomenon. A patient that is fully adherent in certain 
circumstances can be partially adherent in other circumstances. Adherence and nonadherence 
behaviour is so dynamic and varied that perhaps we can never define it properly. Those that 
have worked as clinicians will grasp the variety of the problem, that patient characteristic and 
behaviours are very different and that it is not always easy to find a reason for different types 
of behaviours and that those reasons are not always rational to health professional. 
  
5.2.3. Previous adherence estimates 
Patient’s follow-up of treatment is an important factor for the effectiveness within the mental 
health system. For many years we have had medication that has proven effective in 
schizophrenia and bipolar disorder, but it has been a challenge to motivate the patients to stay 
on the medication. Treatment nonadherence has a major impact on the effectiveness of 
therapeutic interventions and presents many problems in clinical practise (Haynes et al, 
2005).  
 
Schizophrenia 
In 1997 Fenton et al published a review of studies of medication adherence in schizophrenia 
(Fenton et al, 1997). They reported a median nonadherence rate of 55% in 15 studies, with the 
range of 24-88%. In the review of Lacro et al (Lacro et al, 2002), the range of non-adherence 
in 10 studies was 20-56%, with a mean rate of 41%. Lacro et al set strict inclusion criteria for 
studies accepted in the review, where the definition of being adherent was “regularly taking 
medication as prescribed” and if the adherent measure was a self-report, another source was 
needed to estimate adherence. When adopting even stricter criteria for the included studies, 
corresponding to only five study reports, the mean nonadherence rate was 49%.  Nosé et al 
reanalyzed data from 86 studies involving a more heterogeneous sample of patients with 
schizophrenia, psychosis and severe mental disorder (Nosé et al, 2003). They found that 
around 1 in 4 patients failed to adhere to medication or scheduled appointments. Gilmer et al 
studied adherence to antipsychotic medications among Medicaid beneficiaries with 
schizophrenia, between 1998 and 2000, using prescription fills for oral antipsychotic 
medication as a basis for the adherence analysis. They found that 41% were fully adherent, 
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16% were partially adherent, 24% were nonadherent and 19% were excess fillers (Gilmer et 
al, 2004). Valenstein et al found that 40% of patients with schizophrenia or schizoaffective 
disorder, being prescribed with one antipsychotic, had MPR (Medication Possession Ratio) 
<0.80 (Valenstein et al, 2004). The study included 49.003 patients from the Veteran Affairs 
system.  
A number of studies have looked especially at patients with first-episode psychosis 
and adherence to medication. In the early stages of the disorder, patients seem to be more 
responsive to treatment, irrespective of the antipsychotic medication used (Frangou & Byrne, 
2000).  Coldham et al followed 186 patients included in an Early Psychosis Program for one 
year (Coldham et al, 2002). Thirty nine percent dropped out of the program or stopped taking 
their medication, 20% took irregularly and 41% rarely or never missed doses of medication. 
Verdoux et al followed 65 first admitted patients with psychosis for two years (Verdoux et al, 
2000). This was a naturalistic study and 53% interrupted their medication treatment for 2 
weeks or more, against medical advice, during the follow-up. Mojtabai et al followed 182 
patients diagnosed with schizophrenia for two years after first admission (Mojtabai et al, 
2002). Thirty seven percent used antipsychotic medication throughout the first year without 
any gaps in the treatment. Fifty one percent had gaps of 30 days or longer during the first year 
and the mean number of days not taking medication was 204 for that group. In Robinson et 
al´s follow-up of 112 first episode schizophrenia patients, 26% stopped taking antipsychotics 
during the first year of treatment and 30% stopped during maintenance treatment following 
the first relapse (Robinson et al, 2002). The authors emphasized that there were ongoing 
efforts by the research team to educate patients and families with the goal of maintaining 
treatment adherence and that in standard clinical practise such resources were usually less. In 
addition they emphasized that the patients stopped taking antipsychotics despite very good 
overall response to treatment. Data from the West London first episode study, examining 
cross-sectionally 101 patients, 89 of which were still in-patients at the time of admission into 
the study, showed that 44% had poor adherence as defined by the Compliance Rating Scale 
(Mutsatsa et al, 2003).   
In summary, studies of nonadherence in patients with schizophrenia show a wide 
range of adherence. The design of the studies, the definition of adherence and the measures 
used are different. When the study populations are better defined as in the studies of first-
episode patients the rates of nonadherence are more similar. Further studies, where the 
concept of nonadherence is clearer and the study populations are better defined, are needed to 
establish nonadherence rates in schizophrenia.  
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Bipolar disorder 
In bipolar disorder, nonadherence to long-term prophylactic pharmacotherapy ranges from 
20%-66% according to a review by Lingam and Scott, that is commonly referred to in studies 
on adherence in bipolar disorder (Lingam & Scott, 2002). They base this range on two studies 
on adherence in lithium maintenance treatment, conducted in the years 1976 and 1982 (Bech, 
et al, 1976; Connelly et al, 1982) and on an earlier review based on studies from the years 
1966 to 1986 (Cochran, 1986).  In the study of Bech et al 76 patients were studied 
retrospectively, and in the study of Connelly et al 48 patients were followed for 12 months. In 
both studies 25% discontinued lithium treatment. The review of Cochran is based on 13 
studies examining lithium efficacy or lithium compliance. The definition and measures are 
very different from study to study, but in conclusion the rate of nonadherence was 9%-57% 
and the author comments that this range probably underestimated the true problem (Cochran, 
1986). Keck et al found that 64% of a sample of 101 patients admitted for acute mania were 
partially or totally nonadherent in the month prior to admission (Keck et al, 1996). The same 
group followed 140 bipolar patients after discharge from hospital and during the follow-up 
period of one year, 51% were partially or totally non-adherent with prescribed medication 
(Keck et al, 1997). A more recent study accounting for all types of psychiatric medication and 
using a combination of adherence measures found that 60% of euthymic bipolar disorder 
patients were fully adherent over a follow-up for two years, and there was no difference in 
adherence with regards to type of medication (Colom et al, 2000). 
In a large scale study of over 1500 patients followed for 6 years, Johnson and 
McFarland reported that the median continuous use of lithium after first being prescribed was 
76 days and that lithium used by the sample studied, was more often sporadic than continuous 
(Johnson & McFarland, 1996). In a sample of 98 patients being treated with mood stabilizers 
(72 of which took lithium), Scott and Pope found that almost 50% of the patients admitted 
some degree of medication nonadherence in the preceding two years and 32% reported 
missing ≥30% in the preceding month (Scott & Pope, 2002). In a study from 1979 more than 
one-third of patients had stopped their medication two or more times, without proper 
consultation with their psychiatrist, and nine of every 10 patients had at some point 
considered medication withdrawal (Jamison et al, 1979). Sajatovic et al have studied 
treatment adherence to lithium and anticonvulsants and to antipsychotic medication in patients 
with bipolar disorder (Sajatovic et al, 2006; Sajatovic et al, 2007). The study on lithium and 
anticonvulsants involved data on 44,637 bipolar patients identified using the Veterans Affairs 
National Psychosis Registry in the USA. Medication adherence was assessed by using the 
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MPR for lithium, valproate, carbamazepine and lamotrigin. A slight majority of individuals, 
54%, had MPR greater than 0.8 and were considered fully adherent. 25% were partially 
adherent and 21% nonadherent. The same procedure was used in the study of antipsychotic 
medication, where the population counted 73,964 patients and of those 45% were prescribed 
with an antipsychotic. Fifty two percent of this group were fully adherent, 21% were partially 
adherent and 27% were nonadherent.  The last two studies mentioned are interesting in many 
ways. The groups are very large and there are no exclusion criteria, here everyone that has 
been in this database system in the year of the study, is included. There is no study-
intervention that might influence adherence. The adherence measure is pharmacy records 
showing whether the patients are in possession of the prescribed medication or not. There are 
only about half of the patients that possess more than 80% of their prescribed medications, be 
it lithium, an antiepileptic or antipsychotic. We can probably predict that partial adherence 
and nonadherence in this group is even higher, as possessing the medication does not 
guarantee it being taken.  
As a whole, the studies of adherence in bipolar disorder suggest high rates of 
nonadherence. The design of the studies, the definition of adherence and the measures used 
are different. Also in bipolar disorder further studies with clearer definitions and better 
described patients’ populations are needed to learn more about nonadherence to medication.  
 
 
General Medicine 
Partial and nonadherence is not an isolated problem within the mental health system, but is 
widespread throughout medicine. Cramer and Rosenheck reviewed 10 studies reporting 
adherence rates for antidepressive medication, 24 studies for antipsychotic medication and 12 
reports for medication adherence in a range of nonpsychiatric disorders (Cramer & 
Rosenheck, 1998). They found that in patients with psychiatric disorders adherence is lower 
than among patients with physical disorders. Patients receiving antipsychotics took an average 
of 58% of the recommended amount with a range of 24-90%. Patients receiving 
antidepressants took 65% of the recommended amount, with a range from 40-90%. The mean 
adherence rate for patients with physical disorders was 76%, with a range from 60-92%. In 
their review of the studies they compared the measures used and concluded that the difference 
might be largely attributable to the different measures used for estimating adherence.  Despite 
this finding, the problem of nonadherence is big throughout medicine, especially in chronic 
conditions (Osterberg & Blaschke, 2005). Examples of this are diseases like hypertension, 
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asthma and HIV infection. Adherence to therapeutic recommendations in asthma has been 
shown to have a range between 30 and 70% (Bender et al, 1997). For children the average 
medication adherence rate of 48% was compiled in a review of 10 studies (Creer & Bender 
1993). Patients with hypertension are often asymptomatic and experience no immediate 
physical symptoms resulting from missing a dose on occasion or on permanent basis. In the 
longer term however, the inadequate control of elevated blood pressure that is a result of poor 
adherence, increases significantly the risk for costly complications such as stroke, myocardial 
infarction and kidney disease (Burnier, 2006). The range of adherence in studies is wide, but 
they indicate that within a year of antihypertensive therapy, 50% have discontinued the 
treatment (Burnier, 2006). In the treatment of patients with HIV infection or the acquired 
immunodeficiency syndrome, it is essential to achieve 95% adherence to highly active 
antiretroviral therapy. These studies of nonpsychiatric patients show the global nature of 
partial and nonadherence and reflect its complexity and that it is inherent in human nature. 
 
 
5.2.4. Methodological problems 
The variation in reported adherence in severe mental disorders seems to reflect inconsistency 
of study design and methods, which in turn makes it difficult to compare results and limits the 
generalizability of the findings (Lacro et al, 2002; Lingam & Scott, 2002; Awad, 2004; 
Colom et al, 2005;  Velligan et al, 2006). This is a complex problem, as we see discrepancies 
in the definition of adherence in each study, or differences in the way non-adherence is 
addressed (Lacro et al, 2002). Some studies use dichotomous rating (adherent or nonadherent) 
and other use continuous scales. Cut off levels vary and this makes it difficult to find any 
consistent pattern. In one study patients who took 80% of their medication were considered 
adherent (Duncan & Rogers, 1998). In another study, those who reported having stopped their 
medication for 1 week or longer after hospital discharge were deemed non-adherent (Olfson et 
al, 2000). This indicates that a patient that is considered adherent in one study can be 
considered nonadherent in another. Recently it has been proposed that studies investigating 
adherence, report an estimate of the mean percentage of medication taken, even though the 
primary measure of adherence is operationalized otherwise (Velligan et al, 2006). This would 
allow studies to be compared on a common variable. 
Then there is the long standing challenge of how to best measure adherence and non-
adherence.  There are several methods used for adherence measurements, both direct methods 
such as observing the patient swallowing tablets or measuring serum levels of medication and 
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indirect methods such as self-reports and electronic monitoring. Measures of medication 
adherence fall into two basic categories: 1) Objective measures such as pharmacy records, pill 
counts, electronic monitoring and blood plasma levels and 2) Subjective measures based on 
self-rating of the patients, or an interviewer, asking family members or care givers.  
Self-reports and care-giver reports are the most common ways used to assess 
adherence in studies. Velligan et al reviewed literature published between 1971 and 2006 on 
adherence to oral antipsychotic medication in schizophrenia patients and found that more than 
66% (107/161) of studies, used self-report alone or in combination with other measures. Of 
those, 51 used only self-report (Velligan et al., 2006). The self-report measures used varied 
greatly among studies and included ad hoc measures, unspecified interviews, semi structured 
interviews unspecified or specified such as the Rating of Medication Influences, Treatment 
Compliance Interview, Drug Attitude Inventory (DAI), the medication compliance item from 
the Multinomah Community Ability Scale, Medication Aherence Rating Scale (MARS), 
knowledge level, attitudes and insight and asking if they had stopped taking in the past one or 
two weeks. The subjective measures including provider report, significant other report, and 
chart review were used 218 times and were the only measures used in 124 studies (77%). 
Self-report is often criticized as being the least valid measure of adherence due to biases of 
recall and self-presentation (Byerly et al, 2007; Kennedy et al, 1991). Velligan et al found 
that patients and physicians were not able to identify adherence when compared to data from 
electronic monitoring with MEMS (Medication Event Monitoring System, pill bottle caps that 
record the time and date of bottle opening) and pill count (Velligan et al, 2007). Byerly et al 
found that clinicians underestimated levels of nonadherence when compared to MEMS 
(Byerly et al, 2005).   It is clear from the review of Velligan et al, that there are many 
different self-report measures in use and it is questionable if they all measure the same thing 
(Velligan et al, 2006).  
There seem to be at least two types of self-report that measure different behavioural 
constructs. The first type takes the form of retrospective recall of actual medication taking 
events (e.g., “How many times did you take your pills over the past week or month?”) while 
the second is a more general adherence rating (“I took my medication as prescribed” or “I 
often forget to take my medication.” With response assessed as strongly disagree to strongly 
agree). The structure of the self-report is also different. Garber et al, found that the 
concordance of self-report and other measures of medication adherence varied widely based 
on the construct of the measures used (Garber et al, 2004). Questionnaires and diaries had 
moderate to high concordance with objective measures, but interviews were not concordant 
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with objective measures. The reason that self-report is most widely used is the fact that it is 
simple, non-intrusive and not costly. Because self-report is inaccurate, it has been suggested 
that it should be used in combination with an objective measure (Velligan et al, 2006). 
According to Velligan et al´s review of adherence measures, pill count is the objective 
method most widely used (Velligan et al, 2006). Pill counts determine how many pills are 
missing from a container and an estimate of adherence percentage is found. The patients are 
needed to bring their pill bottles in for counting or a more reliable method, unannounced 
home visits are scheduled. In recent years the MEMS caps have been increasingly used in 
adherence studies (Diaz et al, 2004; Byerly et al, 2005; Frangou et al, 2005; Nakonezny & 
Byerly, 2006). They have been considered by some to be the gold standard for measuring 
adherence (Velligan et al, 2006), but even so, they only monitor opening and closing of 
medication bottles, not actual pill ingestion. Patients may take out more than one dose at a 
time, not take any out at all, or fail to replace the cap. Then there is considerable expense in 
obtaining the devices. Thus, the instrument is likely to remain in use only in research, but a 
more general use clinically to monitor adherence is less likely.  
Electronic pharmacy records are an objective, unobtrusive method to determine level 
of adherence. As the availability of electronic pharmacy records is increasing, this opens the 
possibility to study larger groups, but electronic records should not be assumed to be accurate 
or complete. An interesting measure derived from pharmacy data is the MPR. This has in 
recent years been used to estimate adherence in large populations (Valenstein et al, 2002; 
Sajatovic et al, 2007; Sajatovic et al, 2006). Measuring the level of medicine in the blood is 
an objective method that is regarded as highly reliable but it depends on a strict protocol and 
is costly (Baumann et al, 2004; Osterberg & Blaschke, 2005). It is surprising that the method 
has rarely been used in adherence studies, and in the review of Velligan et al, only 7 of 161 
studies used blood levels as part of adherence evaluation (Velligan et al, 2006). Serum 
concentrations are a necessary tool in lithium treatment and are often used to follow up the 
treatment with valproate. Even so, structured interviews and pharmacy records are the most 
widely used instruments in adherence studies of mood stabilizers in bipolar disorder 
(Manwani et al, 2007; Sajatovic et al, 2007; Zeber et al, 2008). Plasma levels of medicine 
indicate if the medication has been taken or not, but do not predict future adherence. It is 
therefore interesting to use plasma levels in combination with a simple self-report to measure 
adherence and this would provide new information.  The availability of plasma measurements 
of different psychotropic medicines varies between countries as there has been lack of easily 
defined therapeutic windows for the newer antidepressants and the second generation 
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antipsychotics (Bengtsson, 2004). In Norway the situation is somewhat special as this has 
been a readily available tool in clinical practice for many years and there exists some 
expertise with regards to reference levels of the different medications (Castberg et al, 2007). 
Thus, in Norway the background for using plasma measurements of psychotropic medications 
in the study of adherence is very good. From the overview of available data on adherence and 
nonadherence in schizophrenia and bipolar disorder it seems that the rate of nonadherence is 
alarmingly high. Even so further studies are needed were adherence measures are better 
defined and multiple measures are used. This has rarely been practised before.  
Selection of patients is a general concern with adherence studies, as those patients that 
deny all treatment usually do not consent to participate in studies. Ethically, this is a problem 
that is impossible to reduce. Even so, it is important to study patient samples that are 
representative of real clinical populations, and naturalistic studies with unselected patients are 
needed to do this. In addition, there is a need of an overview of adherence problems in 
differently organized health care systems. Psychiatric services in Norway are catchment area 
based and publicly funded. Mental health care and treatment is available for anyone suffering 
from severe mental disorder. Studies of adherence in patients with severe mental disorder in 
Scandinavia are sparse. 
From the overview of available data on adherence and nonadherence in schizophrenia 
and bipolar disorder it seems that the rate of nonadherence is alarmingly high, but with a large 
variation between studies and among different patient groups. Further studies are needed 
where available health services in the area, representativity of samples, and adherence 
measures are better defined. Along with this multiple measures of adherence should be used. 
 
5.2.5. Clinical consequences 
Poor adherence with medical treatment has a major impact on clinical outcome and greatly 
increases health care costs (Osterberg & Blaschke, 2005). Many factors affect the outcome in 
schizophrenia treatment. Partial adherence or nonadherence is considered to be one of the 
most important factors (Bebbington, 1995), being strongly associated with an increased risk 
of relapse (Fenton et al, 1997; Robinson et al, 1999).  In patients with schizophrenia, partial 
and nonadherence can set in motion a “downward spiral” of events resulting in inconsistent 
symptom control, relapse and rehospitalisation, which in turn can lead to long-term functional 
disabilities, loss of autonomy, education or employment possibilities, homelessness, a 
likelihood of dropping out of care completely and even suicide (Llorca, 2008). Robinson et al 
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reflect that relapse prevention is a major challenge in the care of patients with schizophrenia 
(Robinson et al, 1999), and in their study of first episode patients they found that five years 
after initial recovery the relapse rate was 82%. With increased relapse rates, the likelihood of 
hospitalization is greater as well. Those who discontinued treatment with antipsychotic 
medication had five times increased risk of relapse. In a sample of 67,000 U.S. veterans with 
schizophrenia who received antipsychotic medication over a 12-month period, those with 
MPR closest to 1.0 had the lowest hospital admissions, and the rates increased with smaller 
MPRs (Valenstein et al, 2002). Poorly adherent patients also had longer duration of 
hospitalization. Gilmer et al also found lower rates of hospitalization in adherent patients 
(14%) than in those who were nonadherent (35%) or partially adherent (24%) (Gilmer et al, 
2004). A study of “revolving door” schizophrenia patients in the USA found that 
nonadherence to medication was the most common reason for hospital admission, cited as the 
cause of admission for 50% of patients (Weiden & Glazer, 1997). Similar results were 
reported from the United Kingdom with medication nonadherence being the reason for 
admission for 55% of patients (Jeffreys et al, 1997). Moreover data from a 1-year cohort 
study of over 4000 patients demonstrated that even small gaps in medication (1-10) days, 
increased the likelihood of hospitalization two-fold, and larger gaps (≥ 30 days) increased the 
likelihood four-fold (Weiden et al, 2004). Law et al reported similar findings (Law et al, 
2008). Verdoux et al looked especially at involuntary readmissions and found them to be six 
times greater in patients with a history of poor medication adherence (Verdoux et al, 2000). 
The negative impact of nonadherence was demonstrated convincingly in a 20-year follow-up 
of patients with schizophrenia in Iceland (Helgason, 1990). Only 54% of patients considered 
to require inpatient care at first contact, accepted hospital admission. Patients that had 
declined at first contact and were admitted later and after further progression in their illness 
were in the end admitted more often and stayed longer in hospital. A recent 3-year 
prospective, naturalistic study examined the relationship between medication adherence and 
long-term functional outcome in schizophrenia (Ascher-Svanum et al, 2006). Adherence was 
assessed using self-report and MPR. Nonadherence was associated with poorer functional 
outcomes, including greater risks of hospitalization, use of emergency psychiatric services, 
arrests, violence, victimizations, poorer mental functioning and greater substance and alcohol 
abuse. Recent data from Denmark indicate that treatment nonadherence is associated with 
increased suicide risk in schizophrenia (Nordentoft, 2007). As it has been shown that long-
term treatment with antipsychotic medication is associated with lower mortality in patients 
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with schizophrenia (Tiihonen et al, 2009), it is likely that improved adherence could lower the 
mortality even further.  
Poor adherence also increases the risk of relapse and rehospitalization in bipolar 
disorder. In the study of lithium maintenance treatment of Johnson and McFarland, they found 
that discontinuation of lithium was associated with increased hospitalization (Johnson & 
McFarland, 1996). In the study of Scott and Pope from 2002, admission rates were 90% in 
those who were nonadherent compared with 10% in those who were adherent (Scott & Pope, 
2002). Keck et al demonstrated that 64% of individuals admitted with manic episode had been 
nonadherent to prescribed mood stabilizers in the month prior to hospitalization and with the 
nonadherent group the severity of mania was greater (Keck et al, 1996). Colom et al followed 
200 bipolar disorder patients for a period of 2 years and reported that those with good 
adherence had fewer hospitalizations over the study period (Colom et al, 2000). Scott and 
Pope explored the relationship between medication adherence, plasma levels of mood 
stabilizers and psychiatric hospitalizations in 98 individuals with mood disorders (Scott & 
Pope, 2002). They found significantly higher admission rates in partially adherent patients 
with sub therapeutic plasma levels. Müller-Oerlinghausen et al have published data 
demonstrating that continuous use of lithium may reduce the risk of attempted or actual 
suicide and that stopping lithium increases the risk of death from suicide or physical 
disorders, particularly cardiovascular disorders (Müller-Oerlinghausen et al, 1996; Müller-
Oerlinghausen, 2001). They reported that adequate long-term lithium treatment significantly 
reduces and even normalizes excess mortality rates in patients with mood disorders. 
Furthermore, a meta-analysis of pooled data from 17,000 patients in 28 studies demonstrated 
that the rate of suicidal acts was 8.6 times higher in patients not receiving regular lithium 
treatment (Müller-Oerlinghausen, 2001). These data show the benefits of long-term 
treatments with lithium, and offer indirect evidence of the potential benefits of adherence to 
mood stabilizers. Gonzalez-Pinto et al confirmed these findings in 2006 reporting a lower risk 
of suicidal acts during closely monitored, highly adherent, long-term lithium treatment 
(Gonzalez-Pinto et al, 2006). 
When partial or nonadherent patients are not identified in the clinic, this can lead to 
unnecessary increases in dosage, a switch in the type of medication or addition of unnecessary 
adjunctive medication. These patients may be incorrectly labelled as having treatment 
resistant illness. 
27 
 
Adherence is very important in clinical trials as we base our knowledge of medical 
treatment on them. An estimated average adherence of 50% rather than 100% in a trial would 
increase the required sample size fivefold in order to maintain the same power (Vermeire et 
al, 2001). 
 
5.2.6. Economical consequences 
When severe chronic illnesses like schizophrenia and bipolar disorder are inadequately 
treated, this increases direct costs of the health care system and indirect costs with lost 
productivity and with the economical burden of disability. Wu et al examined the costs of 
schizophrenia in the United States in 2002 (Wu et al, 2005). They calculated the excess 
annual health care costs to society as the difference in costs between schizophrenia patients 
and their nonschizophrenia controls matched on age, sex and geographic region. Results were 
calculated using a modest prevalence rate of 5.1 per 1000. According to their calculations the 
total excess costs of schizophrenia patients in the United States in 2002 was $62.7 billion. Sun 
et al estimated that the national rehospitalisation cost related to nonadherence to 
antipsychotics was $1479 million in the United States in 2005 (Sun et al, 2007). Given that 
adherence problems are the most common cause of relapse in schizophrenia (Schooler, 2006), 
nonadherence is a significant contributor to increased cost in this population. 
In bipolar disorder the estimated total annual cost in the United States was about $45 
billion in 1991 for the 2 to 2.5 million prevalent cases in the country (Wyatt & Henter, 1995). 
Another study based on the incidence data (95 000 cases) from 1998, estimated total lifetime 
costs of $24 billion (Begley et al, 2001). Durrenberger et al demonstrated in a case series, that 
the cost of care over a period of six years for one nonadherent patient with frequent manic 
relapses was equal to that of 13 patients who adhered to their mood stabilizers (Durrenberger 
et al, 1999).  
It is clear from the last section on clinical consequences that higher relapse rates, more 
frequent hospitalizations and longer duration of relapse is related to partial adherence and 
nonadherence. All this in turn leads to increased cost of the health care system directly as well 
as indirect costs linked to disability and loss of productivity. 
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5.3. Factors predisposing nonadherence 
It has been difficult to identify predictors of medication nonadherence. As with all adherence 
studies, these studies vary in design, definitions and measures as well as in the study samples. 
Even so, there are predictors that seem so be consistently related to adherence, although the 
evidence is still weak for several of them. Factors that have been linked to nonadherence in 
schizophrenia and bipolar disorder  are commonly divided into four groups (Fenton et al, 
1997; Goodwin and Jamison 2007): 1) Patient related factors; including insight, beliefs and 
attitudes towards illness and treatment, history of adherence problems, duration of illness and 
substance use. This group also includes factors like age, gender, ethnicity, marital status and 
education. 2) Illness related factors; including degree of symptoms and cognitive impairment. 
3) Medication related factors; including type and dose of medication and adverse effects. 4) 
Environmental factors; including therapeutic alliance, inadequate out-patient care and the 
involvement of family. 
  
5.3.1. Insight  
There has been considerable interest in the concept of insight in schizophrenia, but less in 
bipolar disorder. In the last twenty years the understanding and definitions of having insight 
into one’s own pathology have changed and there seems to be a consensus among researchers 
that insight is multidimensional and should be measured along a continuum that includes 
awareness of illness, awareness of symptoms and the perceived need for treatment  David 
1990). In the DSM-IV-TR the following is stated: A majority of patients with schizophrenia 
have poor insight regarding the fact that they have a psychotic illness. Evidence suggests that 
poor insight is a manifestation of the illness rather than a coping strategy. It may be 
comparable to the lack of awareness of neurological deficits seen in stroke, termed 
anosognosia. This symptom predisposes the individual to noncompliance with treatment and 
has been found to be predictive of higher relapse rates, increased number of involuntary 
hospital admissions, poorer psychological functioning, and a poorer course of illness 
(Diagnostic and statistical manual of mental disorders : DSM-IV-TR, 2000). As is stated in 
the DSM-IV-TR, schizophrenia patients with poor insight are predisposed to nonadherence. In 
adherence studies insight is the risk factor most consistently associated with nonadherence in 
patients with schizophrenia (Fenton et al, 1997; Lacro et al, 2002). In their review of risk 
factors for nonadherence in schizophrenia Lacro et al found that poor insight was related to 
nonadherence in 10 out of 14 studies addressing the issue (Lacro et al, 2002). Even though 
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there has been a lot of focus on insight in schizophrenia, much less is known about insight in 
bipolar disorder.  
The relationship between insight and nonadherence in bipolar disorder remains unclear 
and few studies have addressed it (McEvoy & Wilkinson, 2000). A recent study showed a 
positive correlation between all 3 dimensions of insight and adherence to medication in 
bipolar disorder (Yen et al, 2005). The few studies that have compared the levels of insight in 
schizophrenia and bipolar disorder found no substantial difference between patients with 
bipolar disorder and schizophrenia, neither during psychotic episode (Amador et al, 1994; 
Pini et al, 2001) nor in remission (Yen et al, 2002). However, the instruments used for 
measuring insight were not validated for patients with bipolar disorder in the mentioned 
studies. Thus there is need for a validated instrument to measure insight in bipolar disorder 
and for studies looking at the relationship between adherence and insight in bipolar disorder. 
Insight has mostly been assessed using semi-structured interview based measures. The Scale 
to Assess Unawareness of Mental Disorders (SUMD) (Amador et al, 1993) is perhaps the 
most widespread scale. It is time consuming and depends on the subjective clinical evaluation 
of the interviewer. It has been proposed that self-report scales might have the benefit of 
obtaining the same information in less time and may provide better control for cofounding 
variables that are conceivably inherent in patient-examiner interaction (Young et al, 2003). 
 
  
5.3.2. Beliefs about medication 
Theoretical paradigms of adherence, such as the Health Belief Model (figure 1, p.31) have 
been developed and adapted to model factors that may determine adherence behaviour 
(Becker & Maiman, 1975). The model provides a useful perspective for understanding how 
patients’ beliefs and attitudes can affect adherence. At the centre of the model is the 
likelihood that a patient will adhere to treatment recommendations. A decision to be partially 
or nonadherent stems from an implicit, subjective assessment of the relative costs and benefits 
(pros and cons) of treatment. If the patient concludes that the benefits of treatment are greater 
than its costs, they will adhere to it. The process is influenced by what patients believe about 
their illness, what its bad effects are and how susceptible they themselves are to those effects. 
Patients´ beliefs and attitudes towards medication have been shown to influence adherence in 
chronically ill patients (Horne & Weinman, 1999). To better understand the reasons for 
nonadherence to medication, Horne et al developed the Beliefs about Medicines 
Questionnaire (BMQ) (Horne et al, 1999). The scale was intended to assess commonly held 
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beliefs about medicines and to simplify the broad range of beliefs people have about specific 
and general medication into “core themes” which are relevant across illnesses and cultural 
groups. These themes could then be evaluated as psychometric scales. Beliefs about specific 
medications prescribed for a certain illness were grouped into two core themes. These were 
their beliefs about the necessity of the prescribed medication for maintaining health now and 
in the future and concerns about the potential adverse effect of taking it. Commonly held 
beliefs about medicines in general were also grouped under two themes. These were general 
beliefs about the intrinsic nature of medicines and the extent to which they are perceived as 
essentially harmful substances that should be avoided if possible and general beliefs about the 
way in which medicines are used by doctors. Horne et al reported that necessity correlated 
positively with adherence to medication, while concern correlated negatively (Horne et al, 
1999). They also found that medication beliefs were more powerful predictors of reported 
adherence than clinical and sociodemographic factors. Horne et al validated the scale. The 
sample in the validation comprised patients with chronic somatic illnesses and a small group 
of patients with psychiatric disorders not otherwise specified (Horne et al, 1999). Hence the 
scale had not been validated in patients with severe mental disorders. 
Attitudes towards medication have been shown to influence adherence to medication 
in schizophrenia (Lacro et al, 2002; Perkins, 2002). In the review of Lacro et al, 8 of 10 
studies addressing negative attitudes towards medication, demonstrated an association (Lacro, 
et al, 2002).  In a study of Cabeza et al, the positive subjective response to antipsychotic 
medication measured by the DAI was significantly correlated to adherence (Cabeza et al, 
2000). There was also a significant correlation between the subjective response and insight. In 
a sample of schizophrenia patients living in supported housing facilities, negative attitudes 
towards medication were associated with nonadherence (Grunebaum et al, 2001). 
In bipolar disorder, attitudes and beliefs towards medication are listed in review 
articles analyzing factors influencing adherence (Lingam & Scott, 2002). In 1979 Jamison et 
al explored the attitudes of 42 patients receiving lithium and the reasons for nonadherence 
(Jamison et al, 1979). Two of the major reasons for nonadherence were that patients disliked 
the idea that their moods were controlled by medication and disliked taking medication as it 
reminded them that they had a chronic illness. In a study of nonadherence with mood 
stabilizers, where attitudes were measured using the Lithium Attitudes Questionnaire 
(Harvey, 1991) with adjustments, partially adherent subjects demonstrated more negative 
attitudes towards the medical treatment (Scott & Pope, 2002). A recent study using Horne´s 
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Necessity/Concerns framework, but utilizing a semi-structured interview in 16 bipolar 
patients, found that patients´ concerns about the medication were associated with both 
intentional and unintentional nonadherence (Clatworthy et al, 2007). 
In earlier studies of attitudes to medication in patients with schizophrenia the DAI was 
most commonly used (Hogan et al, 1983; Hofer et al, 2002;  Day et al, 2005; Adewuya et al, 
2006). A newer scale, the Attitudes towards Neuroleptic Treatment questionnaire, was 
introduced a few years back (Kampman et al, 2000). These scales are developed especially 
for patients with schizophrenia. One of the goals of Horne et al, when developing the BMQ, 
was to construct a scale that could be used broadly across illnesses and cultures. We find this 
a useful goal, which enables researchers to compare different patient groups within both 
psychiatric and medical illness populations. It will enable us to help identify factors that are 
specific for the attitudes of particular groups and this may gain new knowledge to be used for 
improving the effect of pharmacotherapy. 
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5.3.3. Substance abuse 
Research has supported an association between co-occurring substance abuse and adherence 
problems. In Lacro et al´s review of predictors of nonadherence in schizophrenia, an 
association of past or current substance abuse and nonadherence was found in 5 of 9 studies 
analysing this (Lacro et al, 2002). The authors comment that the studies employing a more 
rigorous methodology were more likely to find an association. In the review of Nosé et al it is 
mentioned that substance abuse is related to nonadherence in 8 studies, but the studies are not 
listed (Nosé et al, 2003). Some studies of first episode psychosis or schizophrenia have 
looked at the relationship between substance abuse and adherence problems. In a study 
following 200 patients in an Early Psychosis Program, nonadherent patients demonstrated 
more alcohol and cannabis use than those who were adherent (Coldham et al, 2002) and 
continued cannabis use at one year was one of the most significant determinants of 
nonadherence. In a one year follow-up of first-episode patients, Perkins et al likewise found 
that ongoing substance abuse significantly predicted poor adherence to medication (Perkins et 
al, 2008). In a prospective study  that looks specifically at the use of cannabis as a risk factor 
for nonadherence and treatment dropout in 112  first-episode schizophrenia, the results 
indicated that cannabis use increased the hazard of nonadherence by a factor of 2.4 and the 
hazard of treatment dropout by a factor of 6.4 (Miller et al, 2009). 
 In bipolar disorder substance abuse has been found to have a relationship to 
nonadherence (Lingam & Scott, 2002; Sajatovic et al, 2006; Sajatovic et al, 2007). In a 
follow-up study of 134 bipolar patients, medication adherence was inversely associated with 
the presence of comorbid substance use disorder (Keck et al, 1998). In a study of 115 patients 
with bipolar disorder, lifetime adherence with mood stabilizers was 65.5% in the 58 patients 
with comorbid substance abuse, compared with 82.5% in the 57 patients without substance 
abuse disorders. A couple of interesting studies have also been published during the work 
with the current thesis.  A one year follow-up of 3459 bipolar in- and outpatients showed that 
over the study period, cannabis users exhibited less adherence and had higher overall illness 
severity (van Rossum et al, 2009). In a study of 429 bipolar patients in the US, Baldessarini et 
al found that alcohol dependence was significantly associated with nonadherence and more so 
than other factors (Baldessarini et al, 2008). 
 It is important to continue the work in this field as substance abuse in general and in 
severe mental illnesses is widespread and a serious health problem. Targeting substance abuse 
especially should probably be a priority when developing interventions to improve adherence. 
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5.3.4. Adverse effects 
The burden of side effects and its relationship to nonadherence have got considerable 
attention in research. Side effects are a recognized problem clinically and are often the reason 
for switching to another medication (Weiden & Buckley, 2007). Even so, there does not seem 
to be a clear relationship between more severe side effects and nonadherence. In systematic 
reviews, there is not a consensus regarding this. In a review by Fenton et al, 4 studies are 
mentioned where between one quarter and two thirds of those who discontinue their 
medication unilaterally, cite side effects as their primary reason (Fenton et al, 1997). In a 
review of studies covering the years 1974-1997, Kampman et al mention 6 studies finding 
that side effects reduce adherence, most notably akathisia and akinesia (Kampman & 
Lehtinen, 1999). Nosé et al reviewed 103 studies that reported nonadherene with medication 
and scheduled appointments by psychotic patients. In their list of factors associated with 
adherence and nonadherence, there is no mention of side effects as a predictor of 
nonadherence (Nosé et al, 2003). Lacro et al reviewed 39 adherence articles and found 9 that 
looked especially at side effects (Lacro et al, 2002). Only 1 of the 9 demonstrated an 
association to nonadherence. This came as a surprise to the authors that noted that in the 
reviewed studies systematic ratings of side effects were rarely obtained. Some of the first-
episode studies have examined the relationship of side effects and nonadherence. Robinson et 
al found that parkinsonian side effects significantly increased the likelihood that patients 
would discontinue medication during the first year of treatment (Robinson et al, 2002).  
With the introduction of the second generation antipsychotics, the spectrum of side 
effects has changed. There are as yet, not many studies that have looked at side effects like 
weight gain and sexual side effects and their relationship to nonadherence. Results from a 
survey of 239 schizophrenia patients demonstrated a strong correlation between body mass 
index (BMI) and nonadherence , which was defined by self-report as missing any medication 
in the previous month (Weiden et al, 2004). Further studies are needed that focus on side 
effects of second generation antipsychotics.  
 When studying the literature on predictors for nonadherence in bipolar disorder, side 
effects of medication are not among the factors most often mentioned as predictors. Jamison 
et al suggested that lithium side effects may predict nonadherence (Jamison & Akiskal, 1983). 
A  Danish study from 1976, showed that 16 of 74 patients discontinued lithium treatment  
(Bech et al, 1976). The stated reason for discontinuing was side effects with 12 patients and 
insufficient effect with 4 of the patients. A study of Scott and Pope highlights that it was not 
the actual side effects but the fear of side effects that increased the risk of nonadherence 
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(Scott & Pope, 2002). In a European survey of over 3000 patients, side effects were ranked 
only seventh on a list of patients concerns about treatment (Morselli et al  2003). 
 
  
5.3.5. Neurocognitive factors 
Neurocognition is an important predictor of functional outcome in schizophrenia (Green, 
1996, 2006; Green et al, 2004) and the same relationship seems to exist for bipolar disorder 
(Green, 2006; Martinez-Aran et al, 2007; Burdick et al, 2010). It is reasonable to assume that 
cognitive functions may be related to adherence behaviour, but the relationship between 
neurocognitive dysfunction and nonadherence is still unclear. The studies are sparse, but there 
have been reports from general medicine pointing in the direction that better IQ predicts better 
adherence (Stilley et al ,2004). In studies focusing on schizophrenia, results are mixed 
(Buchanan, 1992; Cuffel et al, 1996; Kemp & David, 1996; Smith et al, 1999; Donohoe et al 
2001; Robinson et al, 2002; Jeste et al, 2003; Maeda et al 2006; Perkins et al 2008; Lepage, et 
al 2010;) and few use extensive neurocognitive testing when measuring cognitive impairment.  
In bipolar disorder there is one study pointing at a relationship between poor treatment 
adherence and cognitive impairment (Martinez-Aran et al, 2009). It is important to explore 
this relationship further.   
  
5.3.6. Other factors 
The relationship of adherence to psychopathology in schizophrenia remains unclear, both in 
terms of significance and the direction of effect. In the review of Lacro et al 4 of 8 studies 
addressing psychotic symptoms found that there was an association between more severe 
psychotic symptoms and nonadherence (Lacro et al, 2002). The presence of mood symptoms 
was associated with nonadherence in 3 of 7 studies. In a study following 400 first-episode 
patients for a year, ongoing depression predicted poor adherence (Perkins et al, 2008). In 
bipolar disorder there is evidence suggesting that there is an association between affective 
symptoms and nonadherence. In a study of 429 bipolar disorder patients, greater numbers of 
affective symptoms and recent mania or hypomania were associated with treatment 
nonadherence.  Keck v found that 64% of individuals admitted with manic episode had been 
nonadherent to prescribed mood stabilizers in the month prior to hospitalization and with the 
nonadherent group the severity of mania was greater (Keck et al, 1996). This however does 
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not prove cause and effect as nonadherence may lead to mania or mania may increase the 
likelihood of nonadherence.  
There was hope that with the second generation antipsychotics, adherence to 
medication would improve, but to date, data is inconclusive regarding this. There are not 
many studies addressing this issue, and those that do, often compare only a few of the 
antipsychotics and not always list the different medication in each group. Rosenheck et al 
found that patients taking clozapine continued their medication for a significantly longer time 
compared to patients taking haloperidol (Rosenheck et al, 2000). In the study of Olfson et al, 
there was a nonsignificant trend suggesting that patients taking SGA (clozapine or 
risperidone) were less likely to become nonadherent than those taking FGA (not described 
which) (Olfson et al, 2000). Cabeza et al found no association between type of antipsychotic 
medication and medication adherence (Cabeza et al, 2000). In the study of Grunebaum et al, 
patients prescribed with SGA had significantly more days of missed medication compared 
with those receiving FGA (Grunebaum et al, 2001). In a 12 month follow-up of Dolder et al, 
patients receiving SGA had significantly smaller gaps in therapy, where patients on FGA had 
approximately 7 days a month without medication and patients on SGA had approximately 4 
days a month (Dolder et al, 2002). Mean adherence rate at 12 months was 55% for the SGA 
group and 50% for the FGA. This difference was not significant and it is clear that adherence 
remained a problem regardless of the type of antipsychotic agent.  A study of 298 California 
Medicaid recipients found that antipsychotic medication was available for 60% of the days 
over a 1 year follow-up and there was no difference in the availability between FGA and SGA 
(Menzin et al, 2003). In the EUFEST study the group taking low-dose haloperidol 
discontinued significantly more often than the groups taking SGA, even though there was no 
difference in efficacy (Kahn et al, 2008). The above mentioned data suggest that there is no 
clear difference in adherence with regards to FGA or SGA, even though the trend seems to 
favour SGA. In only two of the above mentioned studies, comparing FGA and SGA was a 
primary outcome topic (Dolder et al, 2002; Menzin et al, 2003).   
 Regarding the relationship of adherence and sociodemographic factors such as age, 
gender, ethnicity, marital status and education level the results of studies in schizophrenia are 
inconclusive. A majority of studies reviewed by Lacro et al, found no association (Lacro et al, 
2002), but in the review of Nosé et al some studies found a relationship between 
nonadherence and younger age and being male (Nosé et al, 2003).  Some studies of first-
episode schizophrenia patients have found that younger age and earlier onset of illness predict 
nonadherence (Coldham et al, 2002), while others have not found this association (Robinson 
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et al, 2002; Perkins et al, 2008). As in schizophrenia, the findings in bipolar disorder are 
contradictory on sociodemographic factors and adherence to medication (Colom et al, 2005). 
It remains unclear whether male gender is linked to nonadherence, as some studies support 
this (Danion et al, 1987; Keck et al, 1997), but others do not (Colom et al, 2000; Scott & 
Pope, 2002) and some have found that being female predicts nonadherence (Copeland et al, 
2008). Some studies also support that younger age and minority ethnicity are associated with 
nonadherence (Sajatovic et al, 2007), but others do not (Keck et al, 1997). 
 
5.4. Unresolved issues and rationale for the thesis 
So far current knowledge in the field has been outlined, the amount of findings is impressive 
and the task of getting an overview is challenging. However, as guidance for the rationale for 
this thesis, it becomes evident that there are several unresolved issues:  
 Studies with well defined multiple adherent measures (both direct and indirect) are 
sparse and much needed. 
 Adherence studies from representative and well described patient groups are needed. 
There are no such studies from Scandinavia. 
 It is important to continue the work of defining adherence behaviour and establishing 
what characterises partially and nonadherent patients. There are no such studies from 
Scandinavia. 
 Studies investigating the relationship of adherence and neurocognition are sparse. 
 Instruments used to determine factors such as insight and beliefs about medication 
need to be simplified and validated in patients with bipolar disorder. 
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6. Aims of the study 
 
Overall aim 
The overall aim of the thesis was to determine adherence rates in a Norwegian catchment area 
population of patients with severe mental illnesses and to identify predictors for nonadherence 
in this population. 
 
Subaims 
To study the psychometric properties of the Birchwood Insight Scale (IS) in patients with 
severe mental disorders (schizophrenia and bipolar disorder). Furthermore, to determine the 
level of insight in the two patient populations (Paper I). 
 
To evaluate the psychometric properties of the Beliefs about Medicines Questionnaire (BMQ) 
in patients with schizophrenia and bipolar disorder. To examine if beliefs about medicines are 
related to medication adherence in those patients and to explore differences in these beliefs 
between patients with schizophrenia and bipolar disorder. Further, to compare the scores of 
patients with schizophrenia and bipolar disorder to those of patients with severe medical 
disorders (Paper II). 
 
To determine the level of adherence in a representative outpatient sample of patients with 
severe mental disorders based on blood concentration of psychopharmacological agents. 
Furthermore to evaluate the sensitivity and specificity of a short and simple self-report 
method for adherence measurement and compare this with the 5-item Medication Adherence 
Rating Scale (MARS) and provider reports (Paper III). 
 
To identify potential risk factors associated with medication nonadherence in a well-described 
group of patients with schizophrenia and bipolar disorder. Furthermore, to investigate if there 
were different risk factors related to the two diagnostic groups. We included factors suggested 
in earlier studies; including insight, substance abuse, psychiatric symptoms, side effects and 
sociodemographic factors as well as factors not investigated much earlier, such as 
neurocognitive functioning and adverse effects (Paper IV). 
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7. Material and methods 
 
7.1. Design 
This thesis is part of the TOP (Thematically Organized Psychosis) Study. The Oslo TOP 
study is a large, multisite research study, carried out by the University of Oslo in joint 
collaboration with all four University Hospitals in Oslo on the basis of the specialist 
psychiatric services. Patients with SMI from all health care sectors in Oslo are included, the 
main diagnostic groups being schizophrenia and bipolar disorder. Inclusion of patients is 
ongoing. In this thesis, data are based on patients included in the study from May 2003 
through October 2006. The study design is naturalistic, with a translational approach. Thus, a 
number of biological and clinical characteristics of SMI are investigated in order to gain more 
knowledge about the underlying pathophysiological mechanisms of disease.  
The inclusion area covers practically the whole city of Oslo, with a total of 550.000 
inhabitants, living in urban and suburban parts of the capital. The treatment system is 
catchment area based and publicly funded. Patients are referred from primary care. The core 
basis of the psychiatric specialist treatment system is subsector catchment area-based 
outpatient units, with the addition of acute, intermediate and long treatment units. Eligible 
patients were all those meeting study criteria and giving informed written consent of 
participation. The Regional Ethics Committee and the Norwegian Data Protection Agency 
approved the study, and the biobank was approved by the Norwegian Health Directorate. 
 
7.2. Participants 
Inclusion criteria for the TOP Study are broad, consisting of 1) being registered in the 
psychiatric services of any of the 4 University Hospitals in Oslo; 2) aged 18 to 65 years; 3) 
meeting the DSM-IV criteria for any major psychotic or bipolar disorder; 4) understanding 
and speaking a Scandinavian language; 5) having no history of severe head trauma or 
neurological disease; and 6) having an Intelligence Coefficient (IQ) score over 70.  
Patients are included mainly from the outpatient units of each health care sector, but 
also from intermediate and long treatment units. Patients in acute ward treatment are 
considered not currently capable of participation. These patients are instead approached after 
release from hospital, when their mental condition is stabilized. All participants are invited 
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into the study by the clinician responsible for their treatment. Those willing to participate 
receive thorough information of the study aims and procedures from one of the PhD students 
responsible for the assessments, all of them trained psychologists or psychiatrists. The 
inclusion procedure itself is divided into several sessions and in total comprises eight hours or 
more of assessment, including clinical interviews, a physical examination and 
neuropsychological testing. The interviews take place partially at the patient’s regular 
treatment unit, and partially at Oslo University Hospital. 
Participants were continuously being included in the study throughout the study period 
and the study is still ongoing. As a result of this the number of participants grew throughout 
the study period. The purpose of this thesis was to investigate patients with diagnoses of 
bipolar disorder (bipolar I and bipolar II), schizophrenia and schizoaffective disorder (the 
schizoaffective patients were grouped with the schizophrenia patients in analysis). Patients 
with diagnoses of other psychotic disorders were thus excluded from this study. In total 385 
patients were evaluated during the inclusion period. Eighty eight patients did not meet the 
diagnostic criteria. Fifteen patients had not started treatment with medication at the time of 
inclusion and were thus excluded, and two patients withdrew their data after inclusion. 
In paper I the study group consists of patients included from May 2003 to November 
2005. There are 201 patients in this sample, that met the diagnostic criteria for schizophrenia, 
schizoaffective disorder, bipolar I and bipolar II disorder.  
In paper II, III and IV the study group consists of patients included from May 2003 to 
October 2006. There were 280 patients in this sample, patients with bipolar I (n=66) and II 
(n=48) disorders (bipolar group, n= 114), schizophrenia (n=126), schizoaffective (n=30) and 
schizophreniform (n=10) disorder (schizophrenia group, n=166). Patients included in study II, 
III and IV were outpatients. 
 
 
 
 
 
40 
 
Table 1. Demographic and clinical characteristics of study samples. 
 Study I Study II- IV 
Samples Sch. BD I BD II Sch. BD 
N 101 57 37 166 114 
Male, N (%) 61(60) 24(42) 13(35) 95(57) 46(40) 
Age,  
mean(y) 
33 40 37 33 38 
PANSS pos, 
mean 
15 9 10 15 10 
PANSS neg, 
mean 
16 10 11 15 11 
 
Sch.; Schizophrenia, BD; bipolar disorder, PANSS; Positive and Negative Symptoms Scale, neg; negative, pos; 
positive 
 
In study samples II, III and IV serum concentrations of medicines were obtained from 255 of 
280 participants. For these 255 a primary therapeutic agent (PTA) was defined. In the 
schizophrenia group 146 patients (94.8%) were prescribed an antipsychotic agent as the 
primary therapeutic agent. Of those, 55 patients (37.7%) were on monotherapy and 91 
(62.3%) on combined therapy with other antipsychotics, antiepileptics or lithium, or 
antidepressants. Forty nine (33.6%) took two medications, 29 (19.9%) took three, 9 (6.2%) 
took four, 2 (1.4%) took five medications and 2 (1.4%) were taking six different types of 
medications. In the bipolar group 60 patients (59.4%) were prescribed an antiepileptic or 
lithium as their primary therapeutic agent, 23 (22.8%) antipsychotics and 9 patients (8.9%) 
had an antidepressant as their primary therapeutic agent. In this group 34 patients (33.7%) 
were on monotherapy, 34 (33.7%) took two medications, 20 (19.8%) took three medications 
and 4 patients (4.0%) took four medications. In addition, benzodiazepines were prescribed to 
24% of the sample.  
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Table 2. Distribution of Primary Therapeutic Agents (PTA) 
 Schizophrenia 
 (n=154) 
Bipolar 
disorder 
g(n=101) 
Total 
 (n=255) 
First Generation Antipsychotics 
Perphenazine                         
Zuclopenthixol                           
Flupenthixol                        
Levomepromazin 
15            
10            
4             
1 
3          
2  
           
1          
18 
Second Generation Antipsychotics        
Olanzapine                                       
Quetiapine                                       
Risperidone                                
Ziprasidone                                    
Aripiprazole                                      
Clozapine                                      
Amisulpride 
131           
65            
17            
16            
13            
10            
6             
4 
20         
13         
1          
2          
1          
2          
1 
151 
Lithium 0 19 19 
Antiepileptics                            
Lamotrigine                                      
Valproic Acid                        
Carbamazepine                           
Topiramate 
2             
2 
41         
26         
12         
2          
1 
43 
Antidepressants                          
Venlafaxine                                
Ecitalopram                                  
Citalopram                                    
Fluoxetine 
2             
1             
1 
9          
1          
5          
2          
1 
11 
Non-adherent patients not wishing to report 
medication last prescribed 
4 9 13 
 
Within the schizophrenia group, there were 28 patients with schizoaffective disorder. Of those 
22 were prescribed a second generation antipsychotic as the PTA, 2 a first generation 
antipsychotic, 1 lamotrigine and 2 antidepressants. One was nonadherent and did not wish to 
report what was last prescribed. 
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7.3. Methods  
7.3.1. Diagnosis 
Diagnosis was established using the Structured Clinical Interview for DSM-IV-TR-Axis I 
Disorders (SCID-I) (Spitzer et al, 1992). The SCID-I is a semi-structured interview, making 
use of all available information on the patient. In addition to direct information from the 
interviewees and the clinical staff responsible for treatment, the interviewers had access to the 
patient’s complete clinical file. All interviewers finished a training course in SCID assessment 
based on the training program at the University of California Los Angeles (Ventura et al, 
1998). All interviewers participated in regular diagnostic consensus meetings led by a 
clinically experienced professor of psychiatry. To assess reliability for actual study interviews 
a stratified random sample was drawn, consisting of cases from every interviewer. 
Anonymous vignettes describing symptoms and development of the illness were then rated by 
two experts blind to the study ratings. For the 28 vignettes the overall agreement for the nine 
DSM-IV diagnostic categories was 82 % and the overall Kappa 0.77 (95 % CI: 0.60-0.94).   
 
7.3.2 General assessments 
Participants were interviewed regarding their history of mental illness, present symptoms, 
sociodemographics, life style and pharmacological treatment. Symptoms were assessed by the 
following clinical instruments: Inventory of Depressive Symptomatology (IDS) (Rush et al, 
1996), Young Mania Rating Scale (YMRS) (Young et al, 1978) and the Positive and Negative 
Symptoms Scale (PANSS) (Kay et al, 1987). Higher scores on the symptom scales signify 
more symptoms. All interviewers participated in inter rater reliability testing which entailed 
rating of patient videos. An intra class correlation (Shrout & Fleiss, 1979) of 0.73 was 
obtained for the PANSS scale. Global symptoms and psychosocial functioning were measured 
by the Global Assessment of Functioning Scale (GAF), (Pedersen et al, 2007). Side effects 
were measured using the “Udvalg for Kliniske Undersøkelser” (UKU) side effect rating scale 
(Lingjaerde et al, 1987) This scale measures a wide range of side effects divided in the 
categories: psychological, neurological, autonomic and others. After going through the 
different side effects, the patient and the caregiver separately assessed the effect of side 
effects on the patients’ daily life, on a scale from 0-3. All patients were weighed, height was 
measured and BMI calculated. 
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7.3.3 Assessments of adherence 
Three independent types of measures were used: serum concentration, self-report and 
provider-report. 
Serum concentrations 
Fasting blood samples were routinely collected between 9 and 11 am from all patients. 
Patients were instructed not to take their morning dose of prescribed medication prior to the 
blood sampling, according to standard protocol. Serum concentrations of medications were 
analyzed at the Department of Clinical Pharmacology, St. Olav’s Hospital, Trondheim. To 
simplify the analysis, a primary therapeutic agent was defined for patients taking more than 
one medicine. When more than one psychotropic medicine from the same class was used, the 
primary therapeutic agent was defined as the medicine with the highest dose. If the dose range 
was similar, the medicine which had been used for the longest duration was selected as the 
primary therapeutic agent. The reference range for each drug has been derived at the 
laboratory based on their extensive database and long experience with measuring each 
psychotropic drug (Castberg et al, 2007). Of the 280 patients in study samples II, III and IV, 
serum concentrations were missing for 25 and they were excluded from analysis. Reasons for 
the missing data were that some patients refrained from giving blood samples, and some 
samples were not analyzed due to technical problems.  
When considering serum concentrations of psychotropic medicines the 
concentration/dose ratio was used as this gives the best picture of drug intake (Castberg et al, 
2007). An exception from this was lithium, where the serum concentration was used.  By 
using the concentration/dose ratio the serum concentration is divided by daily dosage and thus 
corresponds to the serum concentration per mg of the medication taken daily by the 
individual. By using this measure, the values can be compared directly between subjects 
independently of different drug treatment regimens.  To simplify the analysis, the patients 
were grouped into clusters, as suggested by Velligan et al (Velligan et al, 2006). Three groups 
were defined with regards to the concentration/dose ratio provided by the Trondheim 
laboratory: 1) Not detectable, 2) Low and 3) Within reference range or higher.  
Self-report 
Self-report of adherence was obtained from all patients. They were given a questionnaire by 
the research fellow and marked on a visual analogue scale from 0 – 100% how much of their 
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prescribed medication they had taken the past week. The scale had tick marks with 
corresponding numbers indicating 0, 25, 50, 75 and 100 % level. The patients marked on the 
scale the % intake for each medication they were taking at the time of assessment (see 
appendix fig 1.).  
In order to compare the current simple self-report with other measures, the Medication 
Adherence Report Scale (MARS) was administered. The version used here, MARS-5, is a 
five-item self-report scale developed in the U.K. (Horne & Weinman, 2002).  It was translated 
into Norwegian, with the back translation approved by the original author. MARS-5 has been 
used in earlier studies as a questionnaire to measure self-reported adherence (Horne & 
Weinman, 2002; George et al, 2005; Bowskill et al, 2007). The scale consists of general 
statements about medicines and is not specifically developed for psychiatric patients. The five 
items are: “I forget to take my medicines”, “I change the dose of my medicines”, “I stop 
taking my medicines for a while at times”, “I decide not to take a dose” and “I take less than I 
am instructed to.” There is no time frame specified in this scale (see appendix fig 2.). The 
item responses are scored on a five-point Likert scale where 1 = always, 2 = often, 3 = 
sometimes, 4 = rarely, 5 = never. Scores range from 5-25 with higher scores indicating higher 
adherence. There exist longer versions of the scale that include questions about specific types 
of medication, i.e. for lung diseases. The internal validity of the MARS-5 version used here 
was tested, and Cronbach´s alpha was 0.78. The internal validity in our sample is similar to 
other studies using this version (George et al, 2005). 
Provider report 
In order to compare self-report with information from the providers, a provider-report of 
adherence was obtained from the patients’ case workers who filled in a scale from 0 – 100% 
indicating how much of the prescribed medication they estimated their patients had taken the 
past week.  
Based on the self-report and serum concentrations the study sample in study  IV was 
divided  into adherence groups: 1) Fully adherent patients who with certainty had 100% 
adherence the past week (reported that they took 100% of their medication and the serum 
concentration was within reference level and in correct ratio with the dose) and into, 2) 
Partially adherent group (reported adherence between 12% and 95 %, and/or the 
concentration/dose ratio was lower than the recommended reference values, but with 
detectable medication),  3) No adherence group, that included patients who with certainty had 
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not taken anything (reported that they did not take their medication and/or the serum analysis 
showed no detectable medicines).  In the study sample in study II the partial adherence group 
does not include patients that have reported 100% adherence on self-report, but have  a 
concentration dose ratio that is lower than the recommended values, but not very low.  
  
7.3.4 Assessment of insight 
The Birchwood Insight Scale (IS) (Birchwood et al, 1994) was used in the assessment of 
insight (see appendix figure 3.). This self report inventory consists of eight questions which 
are easy to complete and represent three subscales; awareness of illness (2 items), relabelling 
of symptoms (2 items) and need for treatment (4 items). Due to low internal consistency for 
the subscales (study 1), the usage of the scale was restricted to the total score (see discussion 
9.1.1., p 55). The total score has a range of 0-12, with a score of 9 or more indicating good 
insight. The original 3-point Likert scale (agree-unsure-disagree) was transformed to a 5-point 
scale (agree very much-agree-unsure-disagree-disagree very much).  
The scale was translated into Norwegian and back into English. The authors of the 
scale had no objections to the translation. 
In paper I the PANSS G12 insight item was used to validate the IS scale. 
 
7.3.5 Assessment of beliefs about medicines 
The Beliefs about Medicines Questionnaire (BMQ) (Horne et al, 1999) was used to assess 
patients’ beliefs about their medication (see appendix figure 4.).This questionnaire has been 
validated in patients with chronic illnesses (Horne et al, 1999). The BMQ comprises a specific 
and a general scale and each has two subscales. The BMQ-Specific scale assesses the patients’ 
beliefs about the medication he is prescribed for a specific illness in terms of the necessity of 
taking them and concern about taking them. The scale includes 11 items in two subscales, the 
concern subscale and the necessity subscale. Examples from the 6 item concern scale include: 
“I sometimes worry about the long term effect of my medicines” and “I sometimes worry about 
becoming too dependent on my medicines”.  Examples from the 5 item necessity scale include 
“My health at present depends on my medicines” and “My medicines protect me from 
becoming worse”. The degree of agreement with each statement is indicated on a five point 
Likert scale, ranging from 1= strongly disagree to 5 = strongly agree. Thus the total scores for 
the concern and necessity scales range from 6-30 and 5-25.  The necessity and concern scale 
assess positive and negative attitudes toward medication. An indication of the relative 
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importance of these attitudes for individual patients was obtained by calculating the necessity-
concerns differential, calculated as the difference between necessity and concern scores (Horne 
et al, 1999). The BMQ-General scale assesses more general beliefs or social representations of 
pharmaceuticals as a class of treatment: beliefs that medicines in general are overused by 
doctors and beliefs that medicines in general are harmful, addictive, poisons that should not be 
taken continuously. The scale includes 8 items in two subscales, the overuse subscale and the 
harm subscale.   Examples from the 4 item overuse scale include: “Doctors use too many 
medicines” and “Natural remedies are safer than medicines”. Examples from the 4 item harm 
scale include: “Most medicines are addictive” and “Medicines do more harm than good”. The 
total scores for the overuse and harm scales range from 4-16. 
The scale was translated into Norwegian and back into English. The authors of the scale 
had no objections to the translation. One of the co-authors of paper II, Kjell Ingar Pettersen was 
responsible for the adaptation process.  
 
7.3.6  Neurocognitive assessments 
A comprehensive neuropsychological test battery was administered to all participants by 
psychologists trained by a specialist in clinical neuropsychology. Tests from domains found to 
be sensitive to dysfunction in groups with bipolar disorder or schizophrenia were included. 
These were tests of psychomotor speed, attention, working memory, executive functioning, 
verbal learning and tests of intellectual capacity. In paper IV test results are from five 
neurocognitive domains are used in analysis.  
General cognitive functioning 
Premorbid IQ was assessed with the Norwegian research version of the National Adult 
Reading Test (NART) (Sundet & Vaskinn, 2008). The numbers of errors on the NART were 
calculated into the NART premorbid IQ (Sundet & Vaskinn, 2008). Current IQ was measured 
with Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 2007a). All participants 
showed adequate neuropsychological test effort by scoring less than two errors on the forced 
recognition trial of the California Verbal Learning Test (CVLT-II) (Delis et al, 2004). NART 
was only administered to patients who had gone through their primary schooling in Norway, 
and as such were fluent in the Norwegian language. All analyses of neurocognitive variables 
were limited to these patients. They counted 104 in the schizophrenia group and 90 in the 
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bipolar disorder group. The distribution in the adherence groups was the same after excluding 
patients for the neurocognitive analyses. This was also true for the mean age and gender. 
Domains 
Psychomotor speed. The Digit Symbol test from Wechsler Adult Intelligence Scale (WAIS-
III) (Wechsler, 2003) was included as a measure of psychomotor speed.  
Attention and Working Memory. Digit Span-forwards from WAIS-III (Wechsler, 2003) was 
used as a measure of focused attention. The test requires the person to repeat an increasing 
number of digits in the same order as the test administrator. Score reported here is the 
maximum number of digits repeated.  The Bergen n-back test (Haatveit et al, 2010)  is a 
computer-based test requiring that a button is pressed every time the two numbers displayed 
on the screen are the same as the numbers displayed two screen pictures back (‘2-back’). 
Number of correct responses minus the number of false positives (commissions) was used as 
a measure of working memory.   
Executive functioning. Executive functioning was assessed with the Verbal Fluency test from 
the Delis-Kaplan Executive Function System (D-KEFS) (Delis et al, 2005). Phonetic fluency 
was assessed with the Letter Fluency subtest, where the score is the number of words 
beginning with the letters ‘F’, ‘A’, and ‘S’ generated separately within 60 seconds. Semantic 
fluency was measured with the Category Fluency subtest. The person is given 2 x 60 seconds 
to name first as many animals, then as many boys’ names as possible. Finally, semantic set 
shifting was measured with the Category Switching subtest where the participant is instructed 
to switch between naming fruits and furniture. Number of correct switches within 60 seconds 
is the score reported.   
Verbal learning and Memory. The Logical Memory test from Wechsler Memory Scale 
(WMS-III) (Wechsler, 2007b), was used to assess verbal learning. Two short stories were 
read aloud to the participant who was instructed to repeat them immediately. Score reported is 
the total number of story units recalled. From the CVLT-II (Delis et al, 2004) the total 
number of words repeated immediately after five reading trials of a list of 16 words was used 
as a measure verbal learning. 
Higher scores on the neuropsychological tests signify better performance on all tests. 
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7.4. Statistical analyses 
Statistical analyses were carried out using the software Statistical Package for the Social 
Sciences (SPSS) version 13.0 and 14.0 for Windows. 
 
In paper I reliability analyses of the Birchwood Insight Scale (IS) were performed by 
calculating the internal consistency (method of Chronbach´s alpha) for the 3 subscales and the 
total score in patients with schizophrenia, bipolar I and bipolar II disorder. Bivariate 
correlations between subscales and between subscales and the PANSS G1 insight item were 
calculated using Pearson correlation tests. The same method was applied in paper II when 
analysing the internal consistency for the BMQ-subscales and their intercorrelations. 
Cronbach’s alpha ≥ 0.70 was considered satisfactory, as this has been regarded the necessary 
level for reliable individual comparisons (Perrin et al, 1995). For comparison of continuous 
data (symptom scores, insight scores, scores on BMQ, scores on nevropsychological tests and 
of side effects) between groups, we used a one way analysis of variance (ANOVA) and post 
hoc Bonferroni tests were applied to control for multiple testing when considered appropriate. 
The sensitivity and specificity of the specific and general BMQ scales was tested by 
performing an ROC analysis. 
In paper III mean rates of all adherence measures were calculated. Group differences 
in categorical variables were explored with Chi-square. Correlations were calculated when 
comparing the different adherence measures. This method was chosen to add statistical power 
to the analysis. Due to skewed distribution correlations were calculated as Spearman’s rho. 
Analyses were conducted first for the whole group and then separately for the two diagnostic 
groups (schizophrenia vs. bipolar disorder). 
In paper IV, some variables were dichotomous (using or not using alcohol and/or 
illegal substances), and when looking at the relationship of these variables to the different 
adherence groups, Chi square was calculated, for two of the adherence groups at a time. For 
continuous data ANOVA was used as before. 
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7.5.     Ethical aspects and patients perspective 
Ethics had a special relevance in this project as it implied research involving sensitive 
personal information and use of biological materials from patients with severe psychiatric 
disorders. The potential ethical aspects of the research were paid attention to regarding its 
objectives, the methodology and the possible implications of the results. The central issue was 
that of informed consent and confidentiality – that participants knew how their information 
and blood samples would be used, and that measures to ensure confidentiality were secure. 
All data collection was performed with the approval of the Regional Ethics Committee (ref # 
493-03-01179), and written informed consent was obtained prior to study participation.   The 
following procedures were followed: Each participant had the study explained by a health 
professional and received a written explanation covering the following: purpose of study; 
extent of investigations and interviews; personal information to be stored; how confidentiality 
would be maintained; time of project finish. Patients were explicitly informed; both orally and 
in writing, that participation in the study was voluntary, and that refusal to participate would 
not have any consequences for their future treatment. They were also informed of their right 
to see their own data, and their right to have all data deleted at any occasion. Written informed 
consent was obtained prior to study participation. It they were not able to give informed 
consent, they were contacted later after the acute affective or psychotic episode.  The 
experience was that most patients agreed to participation. The motivation for participating 
was, in addition to the contribution with new knowledge, that participants had the opportunity 
to have a more comprehensive evaluation of something the patients themselves experienced 
as a disturbing condition. If the patient agreed to it, the clinician in charge of the treatment 
would receive a report on clinical findings, diagnostic evaluations and neuropsychological test 
results. The impression was that the evaluations provided by the TOP team were experienced 
as highly useful by both patients and clinicians.  
The collecting and handling of data were approved by the Norwegian Data Protection 
Agency (ref # 2003/2052) to preserve the personal privacy of the participants. The TOP 
database was inspected and approved by the Clinical Monitor at Oslo University Hospital, 
Ulleval. All personal information was treated with the same confidentiality as required within 
the EU countries medical system, and the only persons with access to personal information 
are health care professionals with a duty of confidentiality. All personal identifiers were 
removed, and only a numerical code was used as identifier. This code was stored at a similar 
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security level as the ordinary patient data elsewhere in the hospital system. The biobank was 
approved by the Norwegian Health Directorate (Sosial- og helsedirektoratet, # 05/5851).    
The total evaluation time was several hours, something that sometimes was 
experienced as tiresome. In the case that the participants so whished, or in case the research 
fellow thought that the participant was not able to cooperate optimally, the assessments were 
divided over several days.  Pauses were frequent and encouraged by the professionals. 
Participants did not receive compensation for their participation, but in some cases 
transportation to and from the research centre was provided. After blood sampling participants 
were provided with a light meal as fasting was a necessary part of the blood sampling.    T
 Throughout the study, we, as clinical investigators, were impressed by the interest, co-
operability and tenacity of the participants, without which this research would not have been 
possible. 
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8. Results 
 
Paper I 
The IS scale works well for patients with schizophrenia and bipolar I disorder when the total 
score is used, with Cronbach´s alpha of 0.80 and 0.70 respectively. However it works poorly 
for patients with bipolar II disorder. The subscales showed poor to marginal internal 
consistency, except for “need for treatment” indicating that the usage of the instrument should 
be restricted to the total score. For validation purposes the relationship between the IS total 
score and the PANSS G12 insight item was investigated. A moderate to high correlation was 
found for patients with schizophrenia (r= -0.54, p<0.01) as well as for patients with bipolar I 
disorder (r= -0.49, p<0.01). For patients with bipolar II disorder however, a low to moderate 
correlation was found (r= -0.27), indicating a poor validity of the scale for this diagnostic 
group. The cut off score on the IS total score was set to 9 by the authors. In this study the 
mean IS total scores were similar in the groups with schizophrenia and bipolar I disorder, 8.2 
and 8.5 respectively, reflecting a general attenuated insight in the groups. In the schizophrenia 
group 62% of patients scored below 9 and 56% in the bipolar I disorder group. 
 In conclusion, the IS showed good psychometric properties in schizophrenia, moderate 
properties in bipolar I disorder, and the scale did not work for patients with bipolar II 
disorder. This suggests a cautious use of the scale across different diagnostic groups.   
 
Paper II 
The BMQ works for patients with severe mental disorders. Cronbach’s alpha was satisfactory 
for all subscales, being 0.76 for the BMQ-Specific Concern scale, 0.90 for the BMQ-Specific 
Necessity scale, 0.73 for the BMQ-General Overuse scale and 0.69 for the BMQ-General Harm 
scale. The Concern and Necessity scales seem to measure fairly independent dimensions, 
whereas the Overuse and Harm scales are strongly intercorrelated.  
The Full adherence group scored significantly higher on the Necessity and lower on 
Concern, Harm and Overuse subscales than the No adherence group.  The patients with partial 
adherence had scores in between on all subscales except for general harm, where they had a 
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slightly higher score than the two other groups. The necessity subscale score was much lower in 
the No adherence group than in the other two groups. The mean necessity-concern differential 
for the three groups was: 0.4 for the Full adherence group, -1.5 for the Partial adherent group 
and - 6.0 for the No adherence group, the difference between the No adherence groups and the 
two others was significant (p=0.002). ROC analysis for the BMQ necessity subscale showed 
area under the curve of 0.735. An optimal discrimination was found with a cut off score of 17.5, 
giving a sensitivity of 0.76 and a specificity of 0.56 respectively.  
The mean self reported adherence was 88 % in the schizophrenia-group and 86 % the 
bipolar group.  The schizophrenia-group scored higher on concern and lower on necessity, and 
there was a significant difference in the necessity-concern differential, –1.9 in the schizophrenia 
group and 1.0 in the bipolar group (p=0.002), suggesting that, for the former group, medication 
concerns were more likely to outweigh beliefs about necessity.  Comparison of BMQ-General 
scores between the schizophrenia and bipolar groups showed that patients with schizophrenia 
had more negative attitudes to medicines as a whole. They were significantly more likely to 
perceive medicines as addictive, harmful poisons (higher scores on the General Harm scale) and 
more likely to believe that medicines are overused by doctors (higher scores on the General-
Overuse scale), although the latter did not reach significance. When comparing the BMQ scores 
of our sample of patients with SMI to that of patients with chronic medical illnesses, the 
patients with schizophrenia had significantly lower scores on BMQ-Specific Necessity than the 
patients with chronic medical illnesses. 
In conclusion, the BMQ had satisfactory psychometric properties for use in patients with 
severe mental disorders. Nonadherent patients felt medication to be less necessary and were 
more concerned about it than adherent patients. 
 
Paper III 
Adherence rate defined by serum concentrations within reference level was 61.6 % in the total 
sample, 58.4% for schizophrenia and 66.3% for bipolar disorder, the difference between the 
diagnostic groups was not significant.  The patients’ self report scores overestimated 
adherence, but correlated significantly to health personnel scores (r=0.50), to MARS-5 
(r=0.39) and to serum concentration of medication (r=0.52). The sensitivity for the self-report 
scale for determining adherence using concentration/dose ratio as the objective measure was 
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98% and the specificity was 33%. The positive predictive value was 70 % and the negative 
predictive value was 91 %. 
The MARS-5 mean score in the total sample was 22.0 (SD 2.9, range 13-25). The 
mean adherence last week according to the Provider-report was 85.2%.  
In conclusion, outpatients with severe mental disorders showed relatively good 
adherence to prescribed medication, and self report questionnaires seem to be a valid method 
for measuring adherence. 
 
Paper IV 
In the schizophrenia group, 11 (12.9 %) had a lifetime diagnosis of addiction or abuse in the 
Full adherence group, 25 (48.1 %) in the Partial adherence group and 2 (11.8 %) in the No 
adherence group. The difference between the Full adherence group and the Partial adherence 
group was statistically significant (p < 0.001).  In the bipolar group, 11 (18.6 %) had a lifetime 
diagnosis of addiction or abuse in the Full adherence group, 4 (14.8 %) in the Partial adherence 
group and 7 (46.7 %) in the No adherence group. The difference between the bipolar Full 
adherence group and the No adherence group was statistically significant (p = 0.024). In the 
schizophrenia group the Partial adherence group used significantly more illegal substances in 
the past 2 weeks and 6 months and alcohol in the last six months. In the bipolar group it was the 
Nonadherence group that used significantly more illicit drugs and alcohol in the last two weeks 
and six months. 
The mean (SD) insight score measured on the IS in the schizophrenia group was 8.16 
(2.20) in the Full adherence group, 7.70 (2.15) in the Partial adherence group and 6.38 (2.15) in 
the No adherent group. The difference between the full adherence group and the nonadherent 
group was statistically significant (p<0.05). In the bipolar group the scores were: 8.28 (1.67) in 
the Full adherence group, 8.24 (1.62) in the Partial adherence group and 7.69 (1.68) in the 
Nonadherence group. The bipolar group as a whole scored higher than the schizophrenia group, 
but the difference was not significant. 
Schizophrenia patients with no adherence did better on tests of executive functioning, 
verbal learning and memory and had higher IQ than patients with better adherence.  
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There was a significant association between poor adherence and some autonomic side 
effects; diarrhea, nausea and orthostatism in schizophrenia patients and with orthostatism and 
urine retention in bipolar disorder patients. Otherwise there was no significant relationship 
between side effects and adherence.  
Schizophrenia patients in the Full adherence group had statistically significant higher 
BMI (27.1) than those in the Partial adherence group (24.8). In the bipolar disorder patients 
there were no statistically significant differences of mean BMI between the groups.   
In conclusion, substance use is an important risk factor for nonadherence in our patients 
with schizophrenia and bipolar disorder. Poor insight is also a risk factor, especially in 
schizophrenia. Further, the results suggest that cognitive dysfunction is not a risk factor for 
nonadherence in these diagnostic groups. This supports interventions that focus on reducing 
substance abuse and improving insight in order to increase adherence. 
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9. Discussion 
 
9.1. Discussion of main results 
9.1.1. Psychometric properties of the Birchwood insight scale across diagnoses  
An aim of the current thesis was to study insight in patients with schizophrenia and bipolar 
disorder and its relationship to adherence. To be able to do this an insight measure was 
necessary. The TOP study is a large study, examining many aspects of severe illnesses. There 
are many assessments and the inclusion process is time consuming. It was therefore important 
to use instruments that were simple, easy to complete and not time consuming. In addition it 
was important to limit the subjective assessment of raters to reduce bias of data. There exist 
several instruments for insight measurement. The Insight and Treatment Attitude 
Questionnaire (McEvoy et al, 1989), the Scale to Assess Unawareness of Mental Disorder 
(SUMD) (Amador et al, 1993), the Schedule of Assessment of Insight (SAI and SAI-E) 
(Kemp & David, 1997) are structured or semi-structured researcher-rated interviews. The 
extensive rater-based scale SUMD is widely used and is translated to Norwegian. The use of 
SUMD was evaluated, but the scale was found to be time consuming and thus unpractical for 
use in the TOP Study.  
The use of self-report in psychosis research has become more frequent. Self-reports 
may provide a better control for confounding variables conceivably inherent in the patient-
examiner interaction (Young et al, 2003). Young et al compared the interview based and the 
self-report method in the assessment of insight and postulated that the attendance of a rater 
may add many complexities to the process of self-reflection due to exacerbated cognitive 
problem (Young et al, 2003). In two studies comparing researcher rated (SUMD) and self-
report measures of insight, significant correlations were found in insight scores only when self 
report measures were administered first (Young et al, 2003; Jovanovski et al, 2007). The 
authors offered the explanation that the presence of an active examiner exacerbates cognitive 
problems and social skill deficits and that data are more reliable when the individual makes 
the initial decision regarding his beliefs, without the effect of social influence. 
In this thesis, the Birchwood Insight Scale (IS) was used to assess insight. The results 
indicate that this scale works well for patients with schizophrenia and patients with bipolar I 
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disorder.    However, the scale seems to work poorly for patients with bipolar II disorder. This 
suggests that data obtained with the IS in bipolar II disorder are difficult to interpret.  
Another finding of the current study, is that the subscales of the IS seem to have poor 
to marginal reliability. In the original article of Birchwood et al reliability and validity was 
explored in a mixed psychiatric sample of 133 patients (Birchwood et al, 1994). The authors 
found that the 8 items of the scale could be accounted for by a common factor, therein 
obtaining acceptable construct validity. Cronbach´s alpha was high to very high for the total 
scale, indicating a good internal consistency for the total scale. However, Birchwood et al 
reported subscale inter-item correlation that indicated a fairly low Cronbach´s alpha. This 
taken together with the results of this thesis and the high internal consistency for the total 
score, leads to the conclusion that the scale measures one dimension, and subsequently, the 
usage of the IS should be restricted to the total score.  
The literature on insight and its measurement has focused on schizophrenia, with few 
studies on bipolar disorders. In studies that have compared insight in schizophrenia and 
bipolar disorder, researchers have used instruments developed and validated in schizophrenia 
(Yen et al, 2002; Braw et al, 2011) and studies assessing insight in bipolar disorder patients 
have done the same (Ghaemi et al, 1995; Dell'Osso et al, 2002). The current data suggest that 
if instruments assessing insight in bipolar patients are not validated for that group, the results 
may be questionable. The IS doesn’t include items that measure insight into mood symptoms. 
Recently, the IS has been developed into a scale more specifically designed for patients with 
mood disorders (Sturman & Sproule, 2003). The authors argue that insight scales already in 
use are validated in schizophrenia, schizoaffective or mixed psychiatric samples. These often 
do not reflect the symptomatology and course of illness for patients with mood disorders who 
have not experienced psychotic symptoms.  
There was no difference between the bipolar I disorder and schizophrenia group in the 
total insight score. Yen et al studied insight in patients with schizophrenia and bipolar 
disorder, who were in remission (Yen et al, 2002), using the SAI-E to assess insight. Bipolar 
disorder patients with history of psychosis did not differ from those with schizophrenia. 
However bipolar disorder patients without past history of psychosis had significantly better 
insight than the other two groups (Yen et al, 2002). Others have found the same (Peralta & 
Cuesta, 1998). A new study comparing insight among schizophrenia and bipolar disorder 
patients in remission, found that there was a difference, but this became nonsignificant when 
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adjusting for age (Braw et al, 2011). We cannot exclude the possibility that the poorer 
performance on the IS especially for the bipolar II disorder patients is due to lack of psychotic 
experiences. In our sample of bipolar II disorder patients, 8 individuals had experienced 
psychosis. Eliminating these patients from the analysis did not change the results, which 
suggests that the performance of the bipolar II disorder group was not related to previous 
psychotic episodes. The group of bipolar II disorder patients in our sample is relatively small 
which makes our findings in this group somewhat uncertain. There has not been much interest 
in the study of insight in bipolar disorder patients and we have not found studies that 
differentiate between bipolar I and II disorders when assessing insight. Our results indicate 
that this could be called for. This thesis mainly addresses issues involved in adherence to 
medication. Insight was studied as a factor related of adherence. We did not look at the 
relationships of insight and symptomology or if this had an effect on our results regarding 
insight. Severity of psychopathology has been shown to be significantly related to insight in 
some studies but not others (McEvoy et al, 1989; David et al, 1992; Amador et al, 1993; 
Birchwood et al, 1994; Michalakeas et al, 1994; Ghaemi et al, 1995; Mathew et al, 2010; 
Cassidy, 2010). 
To our knowledge this is the first study to compare insight in schizophrenia and 
bipolar disorder, using an insight measure validated in both groups. 
 
9.1.2. Psychometric properties of the Beliefs about Medicines Questionnaire adherence 
One of the study aims of this thesis was to assess the beliefs and attitudes of patients towards 
their medication. Here a measure was needed. The Beliefs about Medicines Questionnaire 
(BMQ) is a simple self-report scale that had already been translated and adapted into 
Norwegian. The scale has been used in patients with chronic somatic disorders, but has not been 
used in patients with severe mental illnesses until now. In previous studies of attitudes to 
medication in schizophrenia the DAI was most commonly used (Hofer et al, 2002; Day et al, 
2005; Adewuya et al, 2006) and a newer scale was introduced a few years back, the Attitudes 
Towards Neuroleptic Treatment (Kampman et al, 2000). Both are developed especially for 
patients with schizophrenia and the DAI is in some studies used not only as a measure of 
attitudes to medication, but also as an adherence measure (Thompson et al, 2000). One of the 
goals of Horne et al when developing the BMQ was to construct a scale that could be used 
broadly across illnesses and cultures (Horne et al, 1999). In addition the scale is a self-report, it 
58 
 
is simple to administer and not time consuming. As the BMQ had not been validated in a 
population with severe mental disorders, this was necessary in the current study. The result was 
that the scale works for this patient group. The psychometric properties proved satisfactory, 
especially for the specific subscales Concern and Necessity. These two subscales seem to 
measure independent dimensions, and consequently the necessity-concerns differential seems to 
give reliable scores. In contrast to the specific subscales, the two general subscales Harm and 
Overuse, were strongly intercorrelated. They were also fairly strongly correlated with both the 
two specific subscales. We cannot exclude the possibility that the high intercorrelations reflect 
characteristics of our sample, as they were higher in our sample than in Horne’s original sample 
(Horne et al, 1999). The BMQ is a simple tool and the necessity-concerns framework it assesses 
might be of use in clinical practise, to identify patients who have negative perceptions of their 
treatment. This would provide the clinician with valuable information that could trigger a more 
detailed discussion in the clinical setting or other interventions aimed at improving adherence.  
To our knowledge this is the first study to validate the BMQ-scale in a sample of 
patients with severe mental disorders. 
 
9.1.3. Medication adherence in outpatients with severe mental disorder 
The overall aim of the thesis was to investigate adherence rates in a representative outpatient 
sample with severe mental disorders. Multiple measures of adherence were used to arrive at a 
consensus measure. The adherence rate was 61.6% in a sample of 255 outpatients with severe 
mental disorders, with 58.4% in schizophrenia and 66.3% in bipolar disorder (paper III).  As 
pointed out in the introduction of this thesis, the methodology of adherence measures has been 
questioned. We have in this study used multiple measures of adherence as recommended and 
find that this strengthens the validity of the measure. Thus, the present results seem to indicate 
a reasonably high adherence level in the present outpatient sample. However, this is a cross-
sectional study and as such it is difficult to predict the long-term adherence behaviour. In 
addition, the blood levels only represent adherence levels in the last few days before blood 
draw, and it can be discussed how representative they are for more extended periods (Velligan 
et al, 2006). However, blood level measurements are considered better than most other 
methods, but are difficult to do as routine clinical assessment in most countries.  
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In addition to the assessment methods, the adherence level depends on the 
characteristics of the patient sample. In the present study we investigated patients who attend 
outpatient clinics on a regular basis. Other studies of adherence in schizophrenia outpatients 
have also found relatively high adherence (Garavan et al, 1998; Weiss et al, 2002; 
Rettenbacher et al, 2004; et al, 2006) using self-report or provider report. In the past years 
some studies have focused on first-episode schizophrenia patients in naturalistic, follow-up 
studies. Such studies are interesting because of the characteristics of the samples and the 
observation that in the early stages of the disorder, patients seem to be more responsive to 
treatment, irrespective of the antipsychotic medication used (Frangou & Byrne, 2000; Kahn et 
al, 2008). When reviewing these studies of first-episode patients (Verdoux et al, 2000; 
Coldham et al, 2002; Robinson et al, 2002; Mojtabai et al, 2002; Mutsatsa et al, 2003; 
Perkins et al, 2006), they show that by 6 months of treatment, as many as 33% to 44% of 
patients are nonadherent, and by 1 year, as many as 59% (Perkins et al, 2008). It is also 
interesting to look at two recent effect studies in first episode patients. McEvoy et al did a 
RCT of a total of 400 early psychosis patients randomly assigned to olanzapine, quetiapine or 
risperidone and at week 52, all-cause discontinuation rates were 68%, 71% and 71% for all 
three antipsychotics (McEvoy et al, 2007). Overall 41.5% of the 400 patients, discontinued 
against medical advice. In an open RCT conducted by the EUFEST study group, the aim was 
to compare haloperidol to SGA in first-episode patients (Kahn et al, 2008). In all 498 patients 
from 14 European countries were randomly assigned to treatment with haloperidol, 
amisulpride, olanzapine, quetiapine or ziprasidone and were followed for one year. At week 
52, all-cause discontinuation rate was 72% for haloperidol, 40% for amisulpride, 33% for 
olanzapine, 53% for quetiapine and 45% for ziprasidone. Only 13% of the 498 patients 
discontinued because of nonadherence, but other reasons where insufficient efficacy and side 
effects. There are no obvious reasons for these differences in the discontinuation rate in these 
two studies and the study groups are similar. But there is one other marked difference in 
outcome, namely that in the EUFEST study the mean improvement on the PANSS scale was 
considerably better than in the McEvoy study. A recent survey asking 41 leading experts 
about the extent of the problem in schizophrenia and bipolar disorder, showed them to believe 
that these patients in their practises took 51-70% their prescribed medication (Velligan et al, 
2009). 
The health care services are different internationally and this should be taken into 
account when comparing studies of adherence. This study is naturalistic, but in our opinion 
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fairly representative of SMI patients in an outpatient clinic in the Norwegian health care 
system. In Norway the government owns and runs all psychiatric hospitals and outpatient 
departments. The service is based on catchment areas, and is practically free, and the 
treatment is integrated with community based public health care. An important additional 
factor is the high level of therapeutic medication monitoring in clinical practice in Norway. 
Serum measurement of medication is a routine clinical practice in most hospitals, also outside 
University clinics, and for the patients with schizophrenia and bipolar disorder this can be 
expected when attending outpatient clinics. Thus, one might argue that in a well-organized 
health care system, with close collaboration with community services, where the follow-up of 
the patients is careful and extensive including regular blood level measurements, a favourable 
basis for good adherence in this patient group is obtained. Thus, it seems reasonable that the 
current high adherence rates are correct, and it could be speculated that this is due to extensive 
blood serum measurements. However, more studies are needed to answer this question.   
 Even though the current findings indicate higher adherence rates than most previous 
studies, an adherence rate of around 60% should be considered far from acceptable in clinical 
practise. There is need of continuous adherence assessments in clinical practise and simple 
measures such as self-report can be a useful tool in such an assessment. However, direct 
measures such as blood-level measurement of medication should be available for patients who 
seem resistant to treatment or have a history of nonadherence. When partial or nonadherence 
is identified, it is important for clinicians to initiate strategies to improve adherence. Factors 
contributing to patient´s adherence problems need to be identified, and the interventions 
should target these factors specially.  
To our knowledge no previous study has reported adherence levels in a Norwegian 
sample of out-patients with SMI. 
 
9.1.4. Predictors of medication adherence in patients with schizophrenia and bipolar 
disorder 
We have so far established that there is a relatively high adherence in the current sample, 
which is probably reflecting the situation in clinical practice. In addition we have used 
multiple measures in establishing adherence levels and validated instruments used to measure 
insight and beliefs about medication in both diagnostic groups. Having done this, we 
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addressed another of the main aims of the current thesis, namely to identify predictors for 
nonadherence in the study population. An association between poor adherence and reduced 
insight, and the use of illegal substances and alcohol in patients with schizophrenia was 
found. This was similar to the findings in bipolar disorder patients where poor adherence was 
associated with the use of illegal substances and alcohol, while the association to reduced 
insight was on a trend level. Some autonomic side effects were associated with poor 
adherence in both groups, but current symptom levels were not. Better neurocognitive 
functioning was related to decreased adherence in schizophrenia.  
 
Insight 
Poor insight has been considered one of the main predictors of nonadherence in schizophrenia 
(Buckley et al, 2007; Lacro et al, 2002; Perkins, 2002). Our results (paper IV) support this. 
Few studies have directly investigated the relationship between insight and adherence in 
bipolar disorder. Our data suggest that nonadherence in patients with bipolar disorder could 
be associated with poor insight. The nonadherent bipolar disorder patients had lower insight 
than both the fully adherent and the partially adherent patients, but the difference did not 
reach significance. Further research is needed to clarify this. Two previous studies have found 
a relationship between insight and adherence to medication in bipolar patients (Yen et al, 
2005; Copeland et al, 2008). As discussed earlier we used the IS to measure insight after 
validating the scale. A drawback of the validation was that the scale did not work well in 
patients with bipolar II disorder. Despite this, these patients were included in the analysis of 
adherence and insight. This might affect our results on insight. Another factor it that the 
bipolar disorder patients were mostly euthymic at inclusion in the study. Insight in bipolar 
disorder fluctuates and has been shown to be worse in mania and in psychotic depression 
(Peralta & Cuesta, 1998). Follow-up studies of bipolar disorder patients are needed in order to 
evaluate this further. 
 
Beliefs about medication 
In paper II the relationship of the beliefs about medicines, measured with the BMQ, to 
patients’ adherence to medication was investigated. We found that beliefs about necessity and 
the concerns about taking medication were related to adherence in patients with SMI. This is a 
parallel to the finding that patients’ beliefs about medication are a strong predictor of 
adherence in patients with different kinds of chronic illnesses (Horne & Weinman, 1999). 
Two recent studies on patients’ adherence to maintenance antidepressants used the BMQ 
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specific scale and found that adherence was lowest when concern about taking medication 
exceeded the perceived need to take them and highest when perceived need exceeded the 
concerns (Aikens et al, 2005; Brown et al, 2005). The same was found in a study of 223 
bipolar disorder patients (Clatworthy et al, 2009).  A study comparing factors affecting 
adherence to antipsychotics in schizophrenia patients on either depot or oral medication did 
not find that side effects predicted nonadherence in either group, but rather beliefs and 
attitudes towards the medication (Patel et al, 2008) A new study following 112 patients in 
early-episode schizophrenia found that attitudes towards medication predicted medication 
adherence (Baloush-Kleinman et al, 2011). In our sample the schizophrenia group had the 
greatest variation in scores, but the necessity-concern difference was much lower in the 
schizophrenia group than in bipolar disorder group and the groups from Horne et al´s original 
sample. The scores on BMQ-Specific Necessity were lower in our sample of patients with 
SMI and in the psychiatric group in the original sample, than in the sample of patients with 
somatic illnesses. This might reflect that the psychiatric patients have lower insight into their 
illness than the patients with somatic disorders. 
Even though our study is not a longitudinal one, the results support the Health Belief 
Model and the role of attitudes towards medication as a predictor of adherence. 
 
Substance abuse and alcohol 
We found a relationship between poorer adherence and the use of illegal substances and 
alcohol, in both patient groups (paper IV). Interestingly there is a difference in these results. 
In the schizophrenia group it is the Partial adherence group that uses significantly more illicit 
substances and alcohol than the Full adherence group, and more often has a lifetime diagnoses 
of addiction or abuse. In the bipolar disorder group, the nonadherent patients abuse illicit 
substances more often than those who were fully adherent. In a recent study of first episode 
psychotic patients, substance abuse was one of the three strongest predictors of poor 
medication adherence (Perkins et al, 2008). A recent study found a significant increase in 
nonadherence and treatment dropout associated with cannabis use among patients with first-
episode schizophrenia followed over 12 months (Miller et al, 2009). The same was found 
with bipolar disorder patients in a large study of the effect of cannabis on outcome (van 
Rossum et al, 2009). Manwani et al found that lifetime adherence with mood stabilizers was 
lower in patients with co-morbid substance use disorder (van Rossum et al, 2009). Our results 
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are in line with earlier findings that the use of illicit substances and alcohol is a risk factor for 
nonadherence of medication, both in schizophrenia and bipolar disorder. This is of large 
clinical importance, as many clinicians experience that the use of illegal substances is a 
growing problem with young patients suffering from schizophrenia and bipolar disorder. 
 
Adverse effects 
Conflicting evidence exists regarding the role of adverse effects of medication in 
nonadherence (Young et al, 1986; Fenton et al, 1997; Lacro et al, 2002). Our results indicate 
that except for some autonomic side effects, side effects in general cannot be considered a 
main risk factor for nonadherence in our sample. Two recent studies of first-episode patients 
found that neurological side effects increased the likelihood of discontinuation of 
antipsychotics (Robinson et al, 2002; Opjordsmoen et al, 2009). Two other recent studies of 
first-episode patients did not find an association between perceived side effects and treatment 
nonadherence (Mutsatsa et al, 2003; Perkins et al, 2008). With increased use of SGA, 
metabolic side effects have gained more attention, but few have as yet investigated 
specifically the relationship of metabolic side effects and nonadherence. Weiden et al reported 
that in a group of 239 schizophrenia patients, obese individuals were more than twice as likely 
as those with normal BMI to report missing their medication (Weiden et al, 2004). In the 
current study, the Full adherence schizophrenia group had the highest mean BMI and the 
partial adherence group the lowest. This could be due to the naturalistic design, since those 
that stay on the medication are more likely to gain weight and keep it, than those that take 
medication irregularly or stop completely. We do not have data on former weight gain. In the 
bipolar disorder group BMI was not significantly different between the adherence groups. 
This could be due to differences in the type of medication between these two groups, with 
more lithium and antiepileptics used in bipolar disorder. However, these medications also 
cause weight gain.  
Overall, results are still somewhat conflicting. The differences in the literature may be 
related to differently selected patient groups, assessment methods and study design. An 
alternative explanation for the different results regarding side effects could be related to 
attitudes. Nonadherence is more related to the fear of side effects (the concerns), than the 
actual side effects themselves. Adverse effects are one of the factors of the Health Belief 
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Model, but perhaps they affect adherence to medication indirectly through attitudes and 
beliefs. 
Neurocognitive factors 
Few studies using extensive neurocognitive testing have looked at the relationship of 
neurocognition and adherence. In the current study patients were tested with a comprehensive 
cognitive test battery.  An interesting finding of our study (paper IV) was that schizophrenia 
patients with no adherence did significantly better on tests of verbal learning and memory and 
executive function and had significantly higher IQ than adherent patients. Neurocognition is 
an important predictor of functional outcome in schizophrenia (Green, 1996; Green et al, 
2004) and the same relationship seems to exist for bipolar disorder (Green, 2006; Martinez-
Aran et al, 2007; Burdick et al, 2010). Early onset of schizophrenia and poor premorbid 
functioning are associated with greater deficits in attention and executive functioning 
(Silverstein et al, 2002). Neurocognitive dysfunction is also present in bipolar disorder 
(Martinez-Aran et al, 2007; Simonsen et al, 2008), albeit to a lesser degree than in 
schizophrenia (Cahill et al, 2006; Daban et al, 2006), but is thought to be partly responsible 
for the poor functional outcome in bipolar disorder (Martinez-Aran et al, 2009; Burdick et al, 
2010). In studies that have looked at the relationship between neurocognition and adherence 
in schizophrenia, results are mixed (Lepage et al, 2010), but mostly indicate no relationship 
(Adams & Howe, 1993; Buchanan, 1992; Kemp & David, 1996; Smith et al, 1999; Lepage et 
al, 2010). However, a recent study found that higher baseline neurocognitive performance 
was associated with lower medication adherence (Perkins et al, 2008), which is in line with 
our findings. Others have found an association between poor adherence and some form of 
poorer outcome on neurocognitive tests (Cuffel et al, 1996; Donohoe et al, 2001; Robinson et 
al, 2002). Robinson et al found that during the first year of treatment patients with poorer 
premorbid cognitive functioning were more likely to stop antipsychotics and that executive 
functioning was significantly associated with nonadherence after first relapse (Robinson et al, 
2002). The same team had earlier presented data showing that patients who repeatedly went 
off antipsychotics tended to have better premorbid adjustment and better neurocognitive 
performance and suggested that better functioning patients were more likely to deny treatment 
(Robinson et al, 1999). A recent Japanese study suggests that executive functioning, 
education and general IQ may be important factors in individual motivation for medication 
adherence. We found only one study, of Jeste et al, that reported neurocognitive functions to 
be the strongest patient related predictor of the ability to manage medication (Jeste et al, 
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2003). This study used different measures of adherence and neurocognition than the other 
studies discussed here.  Although nonadherent schizophrenia patients seem to perform better 
on neurocognitive tests, their insight is worse than that of either fully or partially adherent. 
The underlying mechanisms of this somewhat surprising relationship in schizophrenia need to 
be further explored. One could speculate that schizophrenia patients with higher 
neurocognitive functions have higher beliefs in their abilities to cope without using 
medication, especially when in remission. One study explored the relationship between 
adherence and neurocognition in bipolar disorder (Martinez-Aran et al, 2009) using both 
extensive neurocognitive tests and multiple adherence measures. In this study both the 
adherent and poorly adherent group showed impairments in attention, psychomotor speed and 
verbal fluency compared to healthy controls. In addition the poor adherence group showed 
worse performance on frontal executive tasks, some of which became nonsignificant when 
controlling for covariates. In the current study there was no difference in neurocognitive 
performance with regards to the adherent groups in the bipolar disorder patients. The bipolar 
disorder group in our study had significantly higher IQ than the schizophrenia group and this 
could affect the results. The current findings have contributed to the much needed data on the 
relationship of neurocognition and adherence and found that cognitive dysfunction does not 
seem to be a risk factor for nonadherence in these diagnostic groups.  
 
We have found, in line with other investigators that the use of illicit substances and 
alcohol is an important risk factor for nonadherence in both schizophrenia and bipolar disorder. 
In addition, lack of insight is a risk factor, especially in schizophrenia. Beliefs about 
medications, reflected in the concerns about taking them and the feeling of the necessity of 
taking them are an important predictor of adherence in both these SMI, just like has been 
established in somatic disorders. The direct role of side effects is more unclear in both 
disorders, even though we did find a relationship between autonomous side effects and 
nonadherence. 
  
Diagnostic differences 
An aim of our study was to compare risk factors for nonadherence in schizophrenia and bipolar 
disorder and if those were the same. The relationship to potential risk factors was stronger in the 
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schizophrenia group. Moreover, the patients in the bipolar disorder group were older, more 
often female, they had longer education, more often held jobs and were more often in a 
relationship. They also had higher IQ. This could affect the results, but is probably also 
reflecting the differences commonly found between these diagnostic groups. And as our sample 
is naturalistic, the results are fairly representative of patients being treated at Norwegian out-
patient clinics.  
 
9.2. Methodology 
9.2.1. Sample representativity 
Psychiatric services in Norway are catchment area based and publicly funded. Outpatient 
clinics are equally distributed and offer a similar quality of care across all districts of the city, 
regardless of socio-economic and socio-cultural differences. Thus, the expectation was that 
the sample would be representative for people with severe mental disorders who live in social 
democratic urban societies, where treatment and care is available for anyone suffering from 
severe mental disorder. The inclusion area for the TOP Study covered practically the whole 
city of Oslo.  The study sample represents an unselected cohort, which was examined within a 
time interval of approximately three and a half years, assuring concordance in time for 
variables susceptible of rapid changes within any given society.  
In Norway, unlike other Scandinavian countries, there was no national Hospital 
Discharge Register with available diagnoses. Thus, it was no impossible to trace patients with 
relevant diagnoses who had not been included, Due to the person data security act, 
information on invitees declining to participate was inaccessible. It was thus not possible to 
estimate the participation rate. However, some degree of selection bias can be assumed. Very 
impaired patients, lacking capacity of informed consent, would not be approached. It also 
seems likely that individuals suffering from severe cognitive deficits, massive negative 
symptoms, or paranoid ideation, would tend to decline participation, even when invited, or 
may not be capable of completing the inclusion procedures. It is also clear from paper IV, that 
the TOP sample turned out to be relatively high-functioning with mean IQ-score within the 
normal range. The mean age of the schizophrenia sample is somewhat lower than that of the 
bipolar disorder sample. In Norway there are specialized clinics for patients with first-episode 
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psychosis where these patients are followed for 5 years. One such clinic recruited patients to 
the TOP and the younger age of the schizophrenia patients might reflect this fact. 
A general concern with adherence studies based on informed consent is the implicit 
selection of patients, as those patients that deny all treatment usually do not consent to 
participate in studies.  One must assume that a proportion of patients that are referred to 
further treatment at the outpatient clinics from in-patient wards, never follow-up the treatment 
and are therefore never selected in studies. As most of the inclusion took place in the 
outpatient clinics, this could bias the sample towards subjects with more factors promoting 
treatment adherence as for instance better insight into need for treatment and more positive 
attitudes towards the treatment in general and its necessity. More specifically for our study, 
we cannot rule out that the clinicians who referred patients selected candidates that were more 
adherent and had less extensive psychopathology. Thus, the TOP sample in the present study 
is probably skewed towards a better functioning and better adherent group than a randomized 
sample of patients with severe mental disorders, taken from the general patient population. 
 
9.2.2. Validity and reliability of assessments 
General assessments 
The instruments used to determine diagnoses and measure symptoms are all widely used in 
clinical psychiatric research and thoroughly tested (see Methods for details). The PANSS is 
developed for schizophrenia, and in this thesis the instrument has been applied to bipolar 
disorder as well. However there are several studies using the PANSS in bipolar disorder, and 
serious validity problems have not been encountered (Daneluzzo et al, 2002; Nitsche & 
Kallert, 2007).  
 The TOP investigators were all clinically experienced psychologists or psychiatrists. 
They received ongoing supervision and participated in regular consensus meetings. In 
addition, all clinical investigators underwent an extensive and structured training program led 
by a well recognized American researcher within the field of diagnostics (Ventura et al, 
1998). To assure inter-rater reliability of the test battery employed, testing was performed, 
yielding very good to excellent results. 
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Adherence measures 
An aim of this thesis was to investigate adherence rate in a population of patients with severe 
mental disorders. After reviewing the literature it became clear that there does not exist a 
simple and widely used measure to assess adherence. A range of measures are available and 
all have limitations. It has therefore been recommended that two or more adherence measures 
should be combined and that at least one of these should be a direct or objective method 
(Sajatovic et al, 2006).  As measurements of serum concentrations of psychotropic medicines 
are readily available in Norway, this was an obvious choice of a direct measure. The main 
limitation of using blood levels is that they only represent adherence level in the last few days 
before blood is drawn and cannot be used to determine adherence over an extended period of 
time, unless repeated samples are taken. In addition the actual blood sampling is burdensome 
to the patient and the analysis is expensive. In the current study we used a laboratory with 
extensive experience in blood level measurements (Castberg et al, 2007), and used established 
values for normal range based on a database of several hundred cases. We also used the 
dose/concentration ratio which controls for the dose of the medication (Castberg et al, 2007), 
but got comparable results using concentration alone.  
Self-report was the other choice of adherence measure. This self report was 
constructed by the research team with the goal that it should be simple and easy for the 
participants to use (for the detailed scale see appendix figure 1). The time frame for the self-
report was the past week. We found that this was more reliable than asking about the past 
month or the past 3 months as some studies have done (Garavan et al, 1998; Velligan et al, 
2007). In addition keeping the time frame short makes the combined measure of serum 
concentration and self-report more reliable. In addition to the two measures mentioned we 
used the MARS-5 a short self-report that measures more general adherence behaviour where 
no time frame is specified. We tested the internal validity of the MARS-5 and Cronbach´s 
alpha was 0.78. The internal validity in our sample was similar to other studies using the same 
version of MARS-5 (Mårdby et al, 2007). We also compared the self-report to provider report 
of adherence. This was available for 182 of the 255 participants used in the adherence 
analysis. In study III the correlation between self-report and serum concentration was 0.52. 
This was highly significant. The sensitivity of the self-report was very good (98%), and so 
was the negative predictive value (89%). However the specificity was poor (33%), whereas 
the positive predictive value was moderate (70%). Our validation of the self-report used, 
suggests that it is a reasonably valid method for measuring adherence (paper III). The 
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correlation between the self-report and the provider report was reasonably good, but less 
between the self-report and the MARS-5. The MARS-5 is as mentioned a more general type 
of scale and as such measures a different construct of adherence. To be able to measure 
adherence more accurately it seems that multiple measures are required and also multiple 
constructs of measure. The measure should not only be able to estimate recent adherence, but 
also adherence or non-adherence in the past. Thus, a more general scale like the MARS-5 
could be useful in this. 
 
9.2.3. Strengths and weaknesses of the studies 
The studies included in this thesis have several strengths. The work was financially supported 
by public grants and was independent of sponsorship from the pharmaceutical industry. The 
design is naturalistic and cross-sectional, with a multi-site approach and broad inclusion criteria. 
Thus, the sample is fairly representative of patients in an outpatient clinic in the Norwegian 
health care system. The sample was well characterized and reliability testing was performed for 
all central items. The study had significant power to obtain statistically significant answers to 
clinically important questions. Psychometric properties of the clinical instruments not used 
before in the current patient groups, were tested in both groups. Multiple adherence measures 
were used with the direct measure of serum concentration of medication used to ascertain 
adherence. 
However, the studies have some weaknesses. The study is cross-sectional and we do not 
have adherence measures over time. The sample of psychiatric patients consisted of patients 
who gave informed consent to participate in a comprehensive research project. As pointed out 
earlier, a general concern with adherence studies based on informed consent is the implicit 
selection of patients, as those patients that deny all treatment usually do not consent to 
participate in studies. This is an important limitation, which due to ethical reasons is impossible 
to reduce. However, the same limitation is present in all the studies in the field requiring 
informed consent. More specifically for the current thesis, one cannot rule out that the clinicians 
who referred patients selected candidates that were more adherent. In addition, participating in a 
study can be considered an intervention and as such may also improve adherence. The study 
sample consists of out-patients that mostly follow their treatment and come to their 
appointments at the clinic. As a consequence of this the No adherence group is small and we 
might miss some important differences.  
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The patients were aware of the fact that blood samples would be taken and serum level 
of medication measured. This might influence the patients’ adherence to the better. However, 
the current blood level measurement protocol is similar to routine clinical practice in many 
clinics in Norway. We have not controlled for factors that could affect medicine blood level 
measurements, such as interactions with other medication or intra and inter individual 
differences in the medication metabolism, but this is probably of less importance because it 
only affects a minority of the results.  
In study II we had no possibility to match our patients with the medical sample which 
was studied 10 years ago, and cannot exclude the possibility that general attitudes to 
medications may have changed somewhat during the 10 year period.  
 
9.3. Clinical implications 
Compared to other studies of adherence the present results seem to indicate a reasonably high 
adherence level in the present outpatient sample (58-66%). Although we concluded that this 
rate is “reasonably” high, it is clear that there is still a long way to go and this should not be 
an acceptable adherence rate in clinical practice. 
There is a need of continuous adherence assessments in clinical practice and simple 
measures such as self-report can be a useful tool in such an assessment. This is easy to do in 
everyday practice, and there are no formal limitations for clinical use of a simple self-report in 
line with the one used in this thesis. However, direct measures such as blood-level 
concentrations of medication should be available for patients who seem resistant to treatment 
or have a history of nonadherence. In addition, mental health services in general should 
prioritize interventions to enhance treatment adherence. 
Our findings support the need to address adherence from the full range of influencing 
factors (patient, illness, medication and environment). The predictive factors were insight, 
beliefs about medication, substance abuse and possibly side effects. Despite not perfect 
sensitivity and specificity, clinicians will be more able to predict adherence if these factors are 
assessed. Clinicians also need to use a collaborative approach in working together with 
patients in order to identify the meaning that patients attribute to the symptoms, prognosis and 
medication. Understanding the patients’ perceptions and accepting these may facilitate greater 
treatment adherence and consequent improved clinical outcomes. 
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It is very important to reduce nonadherence. Based on the current findings together 
with literature, the most effective interventions should focus on reducing substance abuse, 
improving insight and understanding patients’ perceptions and beliefs. Adherence 
interventions are called for and much needed as has been stated by the World Health 
Organization:”Increasing the effectiveness of adherence interventions may have a far greater 
impact on the health of the population than any improvement in specific medical treatments” 
(WHO: Adherence to long-term therapies. Evidence for action 2003). 
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10. Conclusions 
 The Birchwood Insight Scale, a simple self-report scale to assess insight, showed good 
psychometric properties in schizophrenia, medium properties in bipolar I disorder, and 
seems not to work in patients with bipolar II disorder. 
 The level of insight was similar in patients with schizophrenia and bipolar I disorder. 
 The Beliefs about Medication Questionnaire had satisfactory psychometric properties 
for use in patients with severe mental disorders.  
 Nonadherent patients felt medication to be less necessary and were more concerned 
about it than adherent patients. 
 Outpatients with severe mental disorders showed relatively good adherence to 
prescribed medication.  
 Simple self report questionnaires seem to be a valid method for measuring adherence. 
 Substance use is an important risk factor for nonadherence in our patients with 
schizophrenia and bipolar disorder.  
 Poor insight is a risk factor for nonadherence, especially in schizophrenia.  
  Autonomic side effects of medication might be a risk factor for nonadherence. 
 The present findings suggest that reduced cognitive function is not a risk factor for 
nonadherence in patients with schizophrenia and bipolar disorder.  
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11. Errata 
The printed version of this thesis is a reprint of the originally submitted thesis to the 
University of Oslo. 
The following changes have been made: 
Thesis 
 
a) In the Appendix, figure 3, page 90, Birchwood Insight Scale. In the original version 
the column reading, Disagree stood in the middle and the column, reading Unsure to 
the left. The order of these two columns has now been changed according to the order 
in the Norwegian version used when including patients in the study. 
b) In the Appendix, figure 4, page 91, Beliefs about Medicines Questionnaire – 
Specific. In the first column the heading Strongly disagree, has been changed for 
Strongly agree, which is the right version.  
 
Errata in published papers: 
Paper II 
In the description of adherence measures it says: In 20 cases, we did not have blood samples 
and in 51 cases the serum analysis did not give conclusive results regarding adherence. This 
should read: In 25 cases, we did not have blood samples and in 46 cases the serum analysis 
did not give conclusive results regarding adherence. 
Paper III 
a) In the introduction it says: In bipolar disorder, adherence to long-term prophylactic 
pharmacotherapy ranges from 20-66%. This should read: In bipolar disorder, non-
adherence to long-term prophylactic pharmacotherapy ranges from 20-66%. 
 
b) Reference section, reference 35 should read: 
George J, Kong DCM, Thoman R et al. Factors associated with medication 
nonadherence in patients with COPD. Chest 2005;128:3198-3204 
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Appendix 
Figure 1. Self-report of adherence in the past week 
 
How much of your medication do you take? 
1.  How much of medicine 1 did you take in the past week?   
 
Cross on the line: 
_____________________________________________________________________ 
    0%      25%       50%   75%             100%  
 
2.  How much of medicine 2 did you take in the past week?   
 
Cross on the line: 
_____________________________________________________________________ 
    0%      25%       50%   75%             100%  
 
3.   How much of medicine 3 did you take in the past week?   
 
Cross on the line: 
_____________________________________________________________________ 
    0%      25%       50%   75%             100%  
 
4.  How much of medicine 4 did you take in the past week?   
 
Cross on the line: 
_____________________________________________________________________ 
    0%      25%       50%   75%             100%  
 
5.   How much of medicine 5 did you take in the past week?   
 
Cross on the line: 
_____________________________________________________________________ 
0%     25%       50%   75%             100%  
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Figure 2. Medication Adherence Rating Scale – 5 
 
Questions about your use of medicines 
 
 
 Many people find a way to use their medication that suits them. 
 This can be different from the instructions that follow, or what your physician has advised.  
 We would like to ask some questions about how you use your medicines. 
 
Below are statements about how people use their medicines. Please tick for       
each statement in the appropriate box 
 
   Always 
  
   Often  Sometimes Rarely   Never 
I forget to take my medicines      
I change the dose of my medicines      
I stop taking my medicines for a while at 
times 
     
I decide not to take a dose      
I take less than I am instructed to      
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Figure 3. Birchwood Insight Scale 
Please read the following statements carefully and then tick the box which best applies to you. 
 
 
Agree very 
much Agree Unsure Disagree 
Disagree 
very 
much 
1.  Some of my symptoms were made    
     by my mind 
 
   
 
2.  I have always been mentally well 
 
 
   
 
3.  I did not need medication 
 
 
   
 
4.  My stay in hospital was necessary 
 
 
   
 
5. The doctor was right in prescribing  
    medication for me 
 
   
 
6.  I did not need to be seen by a  
     psychiatrist 
 
   
 
7.  If someone said I had a nervous or  
     mental illness they would be right 
 
   
 
8.  None of the unusual things I  
     experienced were due to an illness 
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Figure 4a. Beliefs about Medicines Questionnaire - Specific. 
 
 
 We would like to ask you about your personal views about medicines prescribed for you. 
 These are statements other people made about their medicines 
 Please show how much you agree or disagree with them by ticking the appropriate box. 
 
Your views about medicines prescribed for you Strongly  
agree 
Agree Uncertain Disagree Strongly 
disagree 
My health, at present, depends on my medicines 
     
Having to take medicines worries me 
     
My life would be impossible without my medicines 
     
I sometimes worry about the long-term effect of my medicines 
     
Without my medicines I would be very ill 
     
My medicines are a mystery to me 
     
My health in future depends on my medicines 
     
My medicines disrupt my life 
     
I sometimes worry about becoming too dependent on my 
medicines 
     
My medicines protect me from becoming worse 
     
These medicines give me uncomfortable side effects 
     
 
 
 
 
 
Your views about medicines prescribed for you 
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Figure 4b. Beliefs about Medicines Questionnaire - General. 
 
 
 These are statements other people have made about medicines in general. 
 Please show how much you agree or disagree with them by ticking the appropriate box. 
 
Your views about medicines in general Strongly  
agree 
Agree Uncertain Disagree Strongly 
disagree 
Doctors use too many medicines 
     
People who take medicines should stop their treatment for a 
while every now and a again 
     
Most medicines are addictive 
     
Natural remedies are safer than medicines 
     
Medicines do more harm than good 
     
All medicines are poisons 
     
Doctors place too much trust on medicines 
     
If doctors had more time with patients they would prescribe 
fewer medicines 
     
 
 
 
 
 
Your views about medicines in general 
I

II

III

IV
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Abstract 
Objective: To investigate potential risk factors for medication nonadherence in patients with 
schizophrenia and bipolar disorder.  
Method: A total of 255 patients (154 with schizophrenia and 101 with bipolar disorder) 
underwent clinical assessments, neurocognitive testing and blood sampling.  The patients were 
divided into groups of No, Partial or Full adherence. Relationships to different risk factors were 
analyzed.  
Results: In schizophrenia, use of illegal substances, alcohol and poor insight were related to 
worse adherence. Schizophrenia patients with No adherence did better on tests of executive 
functioning, verbal learning and memory and had higher IQ than patients with better adherence. 
There were higher levels of autonomic side effects in the nonadherence group, but body mass 
index (BMI) was lower in the Partial adherence group than in the Full adherence group. In the 
bipolar disorder patients, there was an association between the use of illegal substances and 
alcohol and poor adherence. There was a nonsignificant trend for poorer insight in bipolar 
patients with No adherence. We found no relationship between adherence behavior and 
neurocognition in the bipolar disorder group.  
Conclusion: Substance use is an important risk factor for nonadherence in patients with 
schizophrenia and bipolar disorder. Poor insight is also a risk factor, especially in 
schizophrenia. Further, the results suggest that cognitive dysfunction is not a risk factor for 
nonadherence in these diagnostic groups. This supports interventions that focus on reducing 
substance abuse and improving insight in order to increase adherence. 
 
Key word: Adherence, predictors, schizophrenia, bipolar disorder 
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Significant outcomes 
 Substance abuse is an important risk factor for partial or nonadherence in patients with 
schizophrenia and bipolar disorder. 
 Poor insight is related to nonadherence in schizophrenia. 
 Neurocognitive impairment is not a risk factor for nonadherence in schizophrenia and 
bipolar disorder. 
 
Limitations 
 The study had a cross-sectional design where adherence was measured at one time-
point. 
 The sample had a high level of adherence, which makes the nonadherence group small. 
 Because of a naturalistic design, nonadherent patients may be underrepresented. 
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Introduction 
In recent years the problem of nonadherence to medication has received increased attention. 
For clinicians to deal with the problem, it is important to identify factors associated with 
nonadherence (1). Understanding these factors is especially important in chronic disorders, as 
it has been shown that adherence is lower when the condition is prolonged (2-4). It is widely 
recognized that nonadherence is a big problem in patients with chronic psychiatric disorders 
(5-10). Schizophrenia and bipolar disorder are two of the most severe psychiatric disorders 
and medication nonadherence is strongly related to the course of illness in these disorders (10-
12). 
The risk factors most consistently associated with nonadherence in patients with 
schizophrenia are poor insight and lack of therapeutic alliance (2, 7). Other important factors 
are negative attitudes towards medication, previous nonadherence, shorter illness duration for 
first-episode patients, substance abuse and inadequate discharge planning and aftercare 
environment (11-13). In bipolar disorder, attitudes toward illness and health beliefs are 
strongly related to nonadherence (8-10, 14). Other important factors are substance and alcohol 
abuse and a comorbid personality disorder. Sosiodemographic factors such as younger age 
and male gender are more disputed as is the role of side effects (10).   
There are some consistencies between the different studies with regards to the different 
risk factors for nonadherence, but some inconsistencies as well, and it is still unclear which 
clinical predictors are most important in schizophrenia and bipolar disorder (7, 8, 10, 15-17). 
One of the reasons for this could be the differences in design and methods in the different 
studies of adherence (7, 8, 10, 18, 19). The measurement of adherence/nonadherence  is a 
long standing methodological problem (18). There are several available methods. Direct 
measures include observing patients swallowing tablets and the measurement of level of 
medicine or metabolites in the blood. Indirect measures cover self reports and electronic 
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medication monitors (1, 20). Few studies have previously used  adherence measures based on 
blood levels of a range of medicines in a large well-characterized sample of patients with 
severe mental disorders (20). A recent review of the literature proposed that all studies of 
adherence should include at least 2 measurements of adherence of which one should be a 
direct or an objective measure (18). 
Neurocognitive dysfunction is a characteristic of both schizophrenia and bipolar disorder 
(21, 22) and an important predictor of functional outcome in schizophrenia (23-26). Some 
studies have found the same relationship in bipolar disorder (25, 27, 28). It is reasonable to 
assume that neurocognition may be related to adherence behavior, but the relationship 
between neurocognitive dysfunction and nonadherence is still unclear. The studies are sparse, 
but there have been reports from general medicine pointing in the direction that better IQ 
predicts better adherence (29). In studies focusing on schizophrenia, results are mixed (30-40) 
and in bipolar disorder there is one study pointing at a close relationship between poor 
treatment adherence and cognitive impairment (41). It is important to explore this relationship 
further.   
 In a previous study we found outpatients with schizophrenia and bipolar disorder to 
have relatively good adherence to their medication(20). In that study, four different measures 
of adherence, including serum level analysis, were utilized.  The aim of the current study was 
to investigate the association of medication nonadherence with a range of potential risk 
factors in this well described group of patients with schizophrenia and bipolar disorder. 
Another aim was to investigate if there were different risk factors related to the two diagnostic 
groups. We investigated factors identified in several earlier studies; including insight, 
substance abuse, symptoms, side effects and sociodemographic factors (2, 7-12, 14), as well 
as factors less investigated earlier, such as neurocognition and body weight (40-42). Based on 
previous literature, we hypothesized that poor insight and the use of illegal substances or 
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alcohol would predict poorer adherence. We also hypothesized that there would be an 
association between degree of neurocognitive dysfunction and poor adherence. 
 
Materials and Methods 
Sample 
This study is a part of the ongoing Norwegian Thematically Organized Psychosis (TOP) 
Study of patients with schizophrenia and bipolar disorders. It is carried out by the University 
and the four university hospitals in Oslo, Norway (20, 43). Patients were recruited from the 
psychiatric departments at these hospitals. Informed consent was obtained by all participants, 
and the Regional Committee for Medical Research Ethics and the Norwegian Data 
Inspectorate approved the study. Exclusion criteria were presence of a diagnosis of 
developmental disorder (IQ<70) or brain damage and age below 18 or above 65 years. The 
sample comprises patients who were consecutively referred to the study from outpatient 
clinics from May 2003 to October 2006.  In total 385 patients were evaluated during the 
inclusion period. Eighty eight patients did not meet the diagnostic criteria. Fifteen patients 
had not started treatment with medication at the time of inclusion and were thus excluded, and 
two patients withdrew their data after inclusion. The sample used in the current study 
consisted of 280 patients with bipolar I (n=66) and II (n=48) disorders (bipolar group, n= 
114), schizophrenia (n=126), schizoaffective (n=30) and schizophreniform (n=10) disorder 
(schizophrenia group, n=166). The sample consisted of 141 men and 139 women; the mean 
age was 35.1 years. The patients were recruited by their clinicians, and thus we do not know 
the exact number of eligible patients who were not referred to the study based on the 
clinicians’ decisions. However, there were 48 clearly eligible patients who were referred but 
refused to participate.  
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All patients underwent a SCID-I diagnostic interview by an experienced clinician (44). All 
interviewers participated in regular diagnostic consensus meetings led by a clinically 
experienced professor of psychiatry. Inter-rater reliability of DSM-IV diagnoses was adequate, 
with a Kappa of 0.77 (95% CI: 0.60 – 0.94) ref.  Sixty four patients (22.9 %) had a lifetime 
diagnosis of alcohol or substance abuse or dependency and within that group 56 (87.5%) had 
used alcohol and 34 (53.1%) had used illicit drugs within the last 6 months.  In the whole group 
90 (32.1%) patients had used illegal substances in the past two years and 75 (26.8%) of those 
had used cannabis.  Of the 280 patients included, serum concentrations were missing for 25, 
and they were excluded from analysis. Reasons for the missing data were that some patients 
refused to give blood samples, and some samples were not analyzed due to technical problems. 
Thus, a total of 255 participants were included in the analysis, with n=154 in the schizophrenia 
and n=101 in the bipolar group. The excluded patients did not differ significantly from the 
group included in the analysis on the following variables: age, gender, education, ethnicity or 
symptoms scores. Demographic and clinical characteristics of patients within the study are 
summarized in Table 1 and the use of illicit drugs and alcohol in the past 2 weeks, 6 months and 
two years is shown in table 2. 
 
Adherence Measures 
All measures were obtained at the time of inclusion in the study. Fasting blood samples were 
routinely collected between 9 and 11 am from all patients. Serum concentrations of 
medications were analyzed at the Department of Clinical Pharmacology, St. Olav’s Hospital, 
Trondheim. To simplify the analysis, a primary therapeutic agent (PTA) was defined for 
patients taking more than one medicine. When more than 1 psychotropic medicine from the 
same class was used, the primary therapeutic agent was defined as the one with the highest 
dose. The PTA in the schizophrenia group were second generation antipsychotics for 131 
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patients, first generation antipsychotics for 15 patients, antiepileptics for 2 patients, 
antidepressants for 2 patients and 4 patients  who were nonadherent did not wish to report the 
medication last prescribed to them.  The PTA in the bipolar disorder group were antiepileptics 
for 41 patients, lithium for 19 patients, second generation antipsychotics for 20 patients, first 
generation antipsychotics for 3 patients, antidepressants for 9 patients and 9 patients did who 
were nonadherent did not wish to report the medication last prescribed to them. The reference 
range for each drug has been derived at the laboratory based on their extensive database and 
long experience with measuring each psychotropic drug (45).  
When considering serum concentrations of psychotropic medicines the concentration/dose 
ratio was used as this gives the best picture of drug intake (45). An exception from this was 
lithium, where the serum concentration was used. To simplify the analysis, the patients were 
grouped into clusters, as suggested by Velligan (18). We defined three groups with regards to 
the concentration/dose ratio provided by the laboratory: 1) Not detectable, 2) Low levels and 3) 
Within reference range or higher.  
Self-report of adherence was obtained from all patients. They were given a questionnaire by 
the research fellow and marked on a Likert scale from 0 – 100% how much of their prescribed 
medication they had taken the past week. Based on both measures we divided the sample into a 
“Full adherence” group; patients who with certainty had 100% adherence the past week 
(reported that they took 100% of their medication and the serum concentration was within 
reference level and in correct ratio with the dose) and into a “No adherence” group; patients 
who with certainty had not taken anything (reported that they did not take their medication 
and/or the serum analysis showed no detectable drugs).  The Full adherence group counted 144 
patients and the No adherence group counted 32. The rest of the sample was assigned to the 
Partial Adherence group which reported adherence between 12% and 95 %, and/or the 
concentration/dose ratio was lower than the recommended reference values, but with detectable 
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medication. Thus the Partial adherence group counted 79 patients. In the schizophrenia group 
there were 85 patients in the Full adherence group, 52 in the Partial adherence group and 17 in 
the No adherence group. In the bipolar disorder group the numbers were 59, 27 and 15.   
  
Risk factor measures 
Symptoms were assessed by the following clinical instruments: Inventory of Depressive 
Symptomatology (IDS) (46), Positive and Negative Symptoms Scale (PANSS) (47) and Young 
Mania Rating Scale (YMRS) (48). For IDS and YMRS the sum score was used and for PANSS 
the sum score and five different components where calculated, the negative, positive, cognitive, 
excitement and depression (49, 50).  
Insight was measured using the Birchwood Insight Scale (IS) (51). This self report scale 
has been validated for a Norwegian sample with mental illness (52). 
 Side effects were measured using the Udvalg for Kliniske Undersøkelser (UKU) side 
effect rating scale (53). This scale measures a wide range of side effects divided in the 
categories: psychological, neurological, autonomic and others. After going through the 
different side effects, the patient and the caregiver separately assessed the effect of side 
effects on the patients’ daily life, on a scale from 0-3. All patients were weighed, height was 
measured and BMI calculated. 
The use of different illicit substances and alcohol use for the last 2 weeks and 6 months 
was obtained with specific questionnaires. The amount of alcohol use was registered and how 
often which type of substance had been used.  
Neurocognitive assessment 
A comprehensive neuropsychological test battery was administered to all participants by 
psychologists trained by a specialist in clinical neuropsychology. Tests from domains found 
to be sensitive to dysfunction in groups with bipolar disorder or schizophrenia were included. 
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National Adult Reading Test (NART) was only administered to patients who had gone 
through their primary schooling in Norway, and as such were fluent in the Norwegian 
language. All analyses of neurocognitive variables were limited to these patients. They 
counted 104 in the schizophrenia group and 90 in the bipolar group. The distribution in the 
adherence groups was the same after excluding patients for the neurocognitive analyses. This 
was also true for the mean age and gender. 
 
General cognitive functioning 
Premorbid IQ was assessed with the Norwegian research version of the National Adult 
Reading Test (NART)(54) . The number of errors on the NART were calculated into the 
NART premorbid IQ (54). Current IQ was measured with Wechsler Abbreviated Scale of 
Intelligence (55). All participants showed adequate neuropsychological test effort by scoring 
less than two errors on the forced recognition trial of the California Verbal Learning Test 
(CVLT-II) (56).  
 
Domains 
Psychomotor speed. The Digit Symbol test from Wechsler Adult Intelligence Scale (WAIS-
III) (57) was included as a measure of psychomotor speed.  
 
Attention and Working Memory. Digit Span-forwards from WAIS-III (57) was used as a 
measure of focused attention. The test requires the person to repeat an increasing number of 
digits in the same order as the test administrator. Score reported here is the maximum number 
of digits repeated.  The Bergen n-back test (58)  is a computer-based test requiring that a 
button is pressed every time the two numbers displayed on the screen are the same as the 
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numbers displayed two screen pictures back (‘2-back’). Number of correct responses minus 
the number of false positives (commissions) was used as a measure of working memory.   
 
Executive functioning. Executive functioning was assessed with the Verbal Fluency test from 
the Delis-Kaplan Executive Function System (D-KEFS)(59). Phonetic fluency was assessed 
with the Letter Fluency subtest, where the score is the number of words beginning with the 
letters ‘F’, ‘A’, and ‘S’ generated separately within 60 seconds. Semantic fluency was 
measured with the Category Fluency subtest. The person is given 2 x 60 seconds to name first 
as many animals, then as many boys’ names as possible. Finally, semantic set shifting was 
measured with the Category Switching subtest where the participant is instructed to switch 
between naming fruits and furniture. Number of correct switches within 60 seconds is the 
score reported.   
 
Verbal learning and Memory. The Logical Memory test from Wechsler Memory Scale 
(WMS-III) (60), was used to assess verbal learning. Two short stories were read aloud to the 
participant who was instructed to repeat them immediately. Score reported is the total number 
of story units recalled. From the CVLT-II (56) the total number of words repeated 
immediately after five reading trials of a list of 16 words was used as an measure verbal 
learning. 
Higher scores on the neuropsychological tests signify better performance on all tests. 
 
Data analysis 
Statistical analyses were carried out using the software Statistical Package for the Social 
Sciences version 14.0 for Windows (SPSS Inc., Chicago, Ill.)  
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When looking at the dichotomous variable of using or not using alcohol and/or illegal 
substances, and the relationship to the different adherence groups, Chi square was calculated, 
for two of the adherence groups at a time. For continuous data (symptom scores, insight 
scores, scores on nevropsychological tests and of side effects) ANOVA was used when 
comparing means in the three different groups. 
 
Results 
Illicit drug use and alcohol use. In the schizophrenia group, 11 (12.9 %) had a lifetime 
diagnosis of addiction or abuse in the Full adherence group, 25 (48.1 %) in the Partial 
adherence group and 2 (11.8 %) in the No adherence group. The difference between the Full 
adherence group and the Partial adherence group was statistically significant (p < 0.001).  In 
the bipolar group, 11 (18.6 %) had a lifetime diagnosis of addiction or abuse in the Full 
adherence group, 4 (14.8 %) in the Partial adherence group and 7 (46.7 %) in the No 
adherence group. The difference between the bipolar Full adherence group and the No 
adherence group was statistically significant (p = 0.024) (Table 3). Table 4 shows the 
relationship of the different adherence groups to the use of all illegal substances, cannabis or 
alcohol in the past 2 weeks and 6 months showing less use of illegal drugs and alcohol in the 
Full adherence groups for both diagnostic categories. 
 
 
Symptomology. Within the schizophrenia group, there was a tendency to higher scores on 
PANSS, IDS and YMRS in the Partial and No adherence groups, but the difference was not 
statistically significant. Within the bipolar disorder group, the scores on the positive and 
excitement component were higher in the Partial and No adherence groups, than in the Full 
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adherence group, but the difference was not statistically significant. This was also the case for 
YMRS. The symptom scores are shown in table 3.   
 
Insight. The mean (SD) insight score measured on the Bircwood Insight Scale in the 
schizophrenia group was 8.16 (2.20) in the Full adherence group, 7.70 (2.15) in the Partial 
adherence group and 6.38 (2.15) in the No adherent group. The difference between the full 
adherence group and the non adherent group was statistically significant (p<0.05). In the 
bipolar group the scores were: 8.28 (1.67) in the full adherence group, 8.24 (1.62) in the 
partial adherence group and 7.69 (1.68) in the non adherent group. The bipolar group as a 
whole scored higher in the insight scale, but the difference was not significant. 
 
Neurocognition 
In the schizophrenia sample, the patients in the No adherence group had significantly higher 
WASI IQ and better verbal learning and  verbal fluency. In the bipolar sample, the results of 
the Partial adherence group where intermediate to the other two groups, but there were no 
statistically significant differences. The results are shown in Table 5.  
  
 
Demographics 
Age, sex, marital status or education was not associated with adherence to medication. 
 
 
Side effects 
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There was a significant association between poor adherence and some autonomic side effects; 
diarrhea, nausea and orthostatism in schizophrenia patients and with orthostatism and urine 
retention in bipolar disorder patients. Otherwise there was no significant relationship between 
side effects and adherence. Schizophrenia patients in the Full adherence group had higher 
BMI than those in the Partial adherence group (table 3) and this was statistically significant. 
In the bipolar patients there were no statistically significant differences of mean BMI between 
the groups.  When dividing the patients into weight groups based on the BMI (normal weight, 
overweight and obese), we found no differences in adherence between the groups. 
 
Discussion 
In the present study we used a reliable measure of adherence and directly compared 
schizophrenia and bipolar disorder patients. The main finding was an association between 
poor adherence and reduced insight, and the use of illegal substances and alcohol in patients 
with schizophrenia. This was similar to the findings in bipolar disorder patients where poor 
adherence was associated with the use of illegal substances and alcohol, while the association 
to reduced insight was on a trend level. Some autonomic side effects  were associated with 
adherence in both groups, but current symptom levels were not. Better neurocognitive 
functioning was related to decreased adherence in schizophrenia. 
Lack of insight is a fundamental attribute of schizophrenia (61) and it makes sense that 
patients who do not realize that they are ill, do not find it sensible to take medication for 
something they do not have. Poor insight has been considered one of the main predictors of 
nonadherence, especially in schizophrenia (7, 15, 61). Our results support this. The literature 
on insight and its measurement has focused on schizophrenia, with few studies on bipolar 
disorder (62, 63).  As predictors of nonadherence  in bipolar disorder patients, attitudes, 
beliefs and expectations are mentioned, but seldom insight as such (8, 17, 64). Our data 
  15 
suggest that nonadherence in patients with bipolar disorder could be associated with poor 
insight, but further research is needed to establish this. Two previous studies have found a 
relationship between insight and adherence to medication in bipolar patients (62, 65). In our 
study we used Birchwood insight scale, which is developed for patients with schizophrenia 
(51). In a validation study in bipolar disorder we found that the scale worked well in patients 
with bipolar I disorder, but not so well in patients with bipolar II disorder (52). This might 
affect our results on insight. Another factor it that the bipolar disorder patients were mostly 
euthymic at inclusion in the study. Insight in bipolar disorder fluctuates and has been shown 
to be worse in mania and in psychotic depression (63). Follow-up studies of bipolar patients 
need to be done in order to evaluate this further. We have in earlier studies looked at beliefs 
about medication and adherence in patients with severe mental illness and found that patients 
with doubts about their need for medication were less adherent (66).  
 We found a relationship between poorer adherence and the use of illegal substances and 
alcohol, in both patient groups. Interestingly there is a difference in these results. In the 
schizophrenia group it is the Partial adherence group that uses significantly more illicit drugs 
and alcohol than the Full adherence group, and more often has a lifetime diagnoses of 
addiction or abuse. In the bipolar disorder group, the nonadherent patients abuse illicit drugs 
more often than those who were fully adherent.  Many clinicians would claim that the use of 
illegal substances is a growing problem with young patients suffering from schizophrenia and 
bipolar disorder. In a recent study of first episode psychotic patients, substance abuse was one 
of the three strongest predictors of poor medication adherence (34). A recent study found a 
significant increase in nonadherence and treatment dropout associated with cannabis use 
among patients with first-episode schizophrenia followed over 12 months (67).  The same was 
found with bipolar disorder patients in a large study of the effect of cannabis on outcome (68). 
Manwani et al found that lifetime adherence with mood stabilizers was lower in patients with 
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co-morbid substance use disorder (69). Our study supports earlier findings that the use of 
illicit substances and alcohol is a risk factor for nonadherence of medication, both in 
schizophrenia and bipolar disorder. 
An interesting finding of our study is that schizophrenia patients with no adherence did 
significantly better on tests of verbal learning and memory, executive function and had 
significantly higher IQ. There is a shortage of adequate studies examining the association 
between adherence to medication and neurocognition. The results in schizophrenia are mixed 
(40), but mostly indicate no relationship (30-33, 40). However a recent study has found that 
higher baseline neurocognitive performance was associated with lower medication adherence 
(34), which is in line with our findings. Even in patients with acute symptoms, neurocognitive 
impairment seems to play little or no role for adherence. Kemp et al concluded that clinical 
variables and attitudes to treatment appeared to be more relevant to adherence in acute 
psychosis than neuropsychological impairment (32). Others have found an association 
between poor adherence and some form of poorer outcome on neurocognitive tests, like 
reduced facial recognition memory (35) and executive functioning (36) as well as a more 
generalized impairment (37). A recent Japanese study suggests that executive functioning, 
education and general IQ may be important factors in individual motivation for medication 
adherence (38). We found only one study, of Jeste et al, that reported neurocognitive 
functions to be the strongest patient related predictor of the ability to manage medication (39). 
This study used different measures of adherence and neurocognition than other similar studies 
we have mentioned.  
Despite the lack of studies showing a relationship, the recently published Expert 
Consensus Guidelines mentioned cognitive impairment as one of the main factors influencing 
medication adherence in schizophrenia. (70). We argue that more studies are needed before 
such claims can be made. In the current study, using extensive neuropsychological test 
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batteries, we found that patients with schizophrenia that do not adhere to medication do 
significantly better on tests of verbal learning and memory, executive function and have a 
higher IQ than adherent patients. This is in line with recently published work of Perkins et al 
(34). Although nonadherent patients seem to perform better on neurocognitive tests, their 
insight is worse than that of either fully or partially adherent. In the bipolar group there was 
no difference in neurocognitive performance with regards to the adherent groups. The 
underlying mechanisms of this somewhat surprising relationship in schizophrenia need to be 
further explored. One could speculate that schizophrenic patients with higher neurocognitive 
functions have higher beliefs in their abilities to cope without using medication, especially 
when in remission. 
 We found no relationship between adherence and symptom severity in the schizophrenia 
group. This finding is in line with earlier findings in schizophrenia (7), even though some 
have found an association between psychotic symptoms (71), or depressive symptoms (34) 
and lower adherence. In the bipolar disorder group the nonadherent patients scored higher on 
the excitative and positive component on PANSS and on the YMRS scale. The difference did 
not reach significance, but goes in the same direction as found in earlier studies (72).  
 Many clinicians would claim that patients complain of side effects as a reason for 
discontinuing medication, but despite several studies, there is still conflicting empirical 
evidence. Lacro et al reported in their review that only one of nine studies found that the 
severity of side effects predicted adherence problems (7). Fenton et al and Young et al found 
that in the majority of studies they reviewed there was a direct association (2, 7, 73). Our results 
indicate that except for some autonomic side effects, side effects in general cannot be 
considered a main risk factor for nonadherence. In a recent study of first-episode patients, 
parkinsonian side effects significantly increased the likelihood of discontinuation during the 
first year of treatment. (36). Another first episode study suggested the same, namely that 
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patients found neurological side effects worse than weight gain and sedation,, leading to more 
discontinuation among those who used first-generation antipsychotics (74). Two other recent 
studies of first-episode patients did not find an association between perceived side effects and 
treatment nonadherence (34, 75). Metabolic side effects have gained attention recently and 
Weiden et al reported that in a group of 239 schizophrenia patients, obese individuals were 
more than twice as likely as those with normal BMI to report missing their medication (42). In 
our study, the Full adherence schizophrenia group had the highest mean BMI and the partial 
adherence group the lowest. This could be due to the naturalistic design, since those that stay on 
the medication are more likely to gain weight and keep it, than those that take them irregularly 
or stop completely. We do not have data on former weight gain. In the bipolar disorder group 
BMI was not significantly different between the adherence groups. This could be due to 
differences in the type of medication between these two groups, with more lithium and 
antiepileptics used in bipolar disorder. However, these medications also cause weight gain. 
Overall, results are conflicting. The differences in the literature are most likely related to 
differently selected patient groups, assessment methods and study design. 
An aim of our study was to compare risk factors for nonadherence in schizophrenia and 
bipolar disorder and if those were the same. The relationship to potential risk factors was 
stronger in the schizophrenia group, but this could be due to higher number of patients. 
Moreover, the patients in the bipolar disorder group were older, more often female, they have 
longer education,  
more often hold jobs and are more often in a relationship. They also have higher IQ. This 
could affect the results, but as our study is naturalistic, this sample represents the features of 
fairly representative patients being treated at Norwegian out-patient clinics.  
The present study has several limitations. The study is cross-sectional, and we do not have 
observations over time. A general concern with adherence studies based on informed consent is 
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the implicit selection of patients, as those patients who deny all treatment usually do not 
consent to participate in studies. In addition we cannot rule out that the referring clinicians 
selected more adherent candidates. Participating in a study can in itself be considered an 
intervention and may improve adherence. The patients were aware of the fact that blood 
samples would be taken and might therefore have been more adherent at the time of the study. 
We have pointed out earlier that adherence in general is good in this group and therefore we 
might have a biased group with regards to nonadherence and the relationship to neurocognitive 
factors (20). Our group consists of out-patients that mostly follow their treatment and come to 
their appointments at the clinic. As a consequence of this the No adherence group is small and 
we might miss some important differences.  
In conclusion, the use of illicit substances and alcohol is an important risk factor for 
nonadherence in both schizophrenia and bipolar disorder. Insight is also a risk factor, 
especially in schizophrenia. Side effects of medication might be a risk factor for 
nonadherence. This supports interventions that focus on reducing substance abuse, improving 
insight and using medications with few side effects. The relationship to psychiatric symptoms 
is more unclear, and it is important to study adherence in different phases of bipolar disorder.  
Further, cognitive dysfunction does not seem to be a risk factor for nonadherence in these 
diagnostic groups. 
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Table 1. Demographic and clinical characteristics of the study sample.  
 Schizophrenia 
(n=154) 
 
Bipolar Disorder 
(N=101) 
 
          
Male gender, n (%) 84 (54) 41 (41) * 
Age, mean (SD) 33.2 (9.3) 38.8 (12.1) ** 
European origin, n (%) 122 (79.2) 94 (93) ** 
Married or cohabiting, n (%) 25 (16.2) 33 (32.7) ** 
Education, mean years (SD) 12.6 (2.7) 14.8 (3.1) ** 
Currently employed, n (%) 16 (10.4) 32 (31.7) ** 
Co-morbid addiction n (%) 38 (21.4) 22 (21.8)  
PANSS positive symptoms (SD) 15.2 (5.6) 9.4 (2.4) ** 
PANSS negative symptoms (SD) 15.3 (6.0) 10.4 (3.6) ** 
PANSS positive component (SD) 12.9 (5.0) 6.9 (2.4) ** 
PANSS negative component (SD) 20.2 (7.4) 14.5 (4.8) ** 
PANSS excitement component (SD) 7.6 (2.6) 7.1 (2.0)  
PANSS depressive component (SD) 11.8 (4.3) 10.4 (3.6) ** 
PANSS cognitive component (SD) 5.3 (2.1) 3.8 (1.2) ** 
YMRS mania symptoms (SD) 5.7 (4.9) 2.4 (3.2) ** 
IDS depressive symptoms (SD) 17.9 (12.5) 16.0 (11.8)  
IS (SD) 7.8 (2.2) 8.2 (1.6)  
NART pre-morbid IQ (SD) 112.1 (4.1) 113.2 (4.2) * 
PANSS, Positive and negative Syndrome Scale; YMRS, Young Mania Rating Scale; IDS, Inventory 
of Depressive Symptomatology; IS, Birchwood Insight Scale; NART, National Adult Reading Test. 
* p<0.05, ** p<0.01 (Means compared using One way ANOVA and Chi-square used when 
dichotomous variables) 
 
 
Table 2. Use of illicit drugs and alcohol in the past 2 weeks, 6 months and 24 months 
Use of illicit 
drugs  (%) 
 
Past 2 weeks Past 6 months Past 24 months 
Schiz Bipolar Schiz Bipolar Schiz Bipolar 
Cannabis 12.1 4.4 21.7 12.3 27.1 26.3 
Amphetamine 2.4 0 10.2 1.8 17.5 2.6 
Other 1.2 0 8.4 1.8 9.6 3.5 
All use 12.8 5.3 26.8 15.8 34.5 28.9 
 
Use of alcohol 
(%) 
48.2 69.3 76.5 83.2 81.3 88.6 
   
Schiz; Schizophrenia, Bipolar; Bipolar disorder 
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